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ABSTRACT
Alzheimer's disease is a prevalent disease that affects roughly 5.4 million individuals
each year (Fisher et al., 2018). Understanding the prevalence of Alzheimer's disease within the
bioarchaeological record can help anthropologists gain an understanding of a population's health
while also understanding the potential social ramifications. Trace element analysis is a valuable
tool that allows bioarchaeologists to gain insight into individuals' health and development within
the context of the past. In bioarchaeological studies, hair analysis has been used to map the
nutritional status and migration patterns of individuals of past peoples, with recent studies
focusing on disease prevalence. Analysis of hair as a biosource of information for trace element
analysis is highly useful for various reasons such as its ability to withstand taphonomic
processes, the high concentration of elements within its structure, and the expanded time frame
of an individual's life it represents. This study uses ICP-MS to conduct the trace element analysis
of copper (Cu), zinc (Zn), manganese (Mn), iron (Fe), selenium (Se), and aluminum (Al) to
create a profile of hair from 13 bioarchaeological individuals from Romano-Christian Kellis 2
cemetery) in the Dakhleh Oasis, Egypt and 13 modern individuals from the Florida State Willed
Body Program at The University of Central Florida Medical School with confirmed or suspected
Alzheimer's disease to conduct a comparative analysis between the two samples. High levels of
the aforementioned elements have been noted as resulting in a high toxicity level within the
brains of individuals with Alzheimer's disease (Dormandy, 1989). Results indicate that eight
individuals from Kellis may have had neurological diseases, including Alzheimer’s disease,
Parkinson’s disease, Huntington’s disease, and mood disorders (e.g., depression, anxiety, and
ADD/ADHD). Additionally, health profiles for each individual from Kellis were constructed and
show the possibility of other pathological conditions such as cardiovascular disease, kidney/liver
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disease, anemia, and diabetes mellitus. This research provides a deeper understanding of health
and illness in the Dakhleh Oasis during the Romano-Christian period, in conjunction with a
holistic understanding of the social care practices as discussed through the theoretical framework
of the Bioarchaelogy of Care theory.
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Thorns may hurt you; men desert you; sunlight turn to fog;
but you're never friendless ever, if you have a dog.”
― Douglas Malloch
To Kevin, With love
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CHAPTER ONE:
INTRODUCTION
Bioarchaeologists are uniquely equipped to study and interpret the lives of past peoples
via their health, development, and behaviors. This is done by testing hypotheses and drawing
inferences about diet and nutrition, health and disease, demography, and physical behavior and
lifestyle in the past from skeletal collections (Larsen, 2018). When coupled with written records,
skeletal collections provide a bounty of information regarding the history of a population. The
direct nature of skeletal remains allows bioarchaeologists to access a variety of information
through various techniques such as stable isotope testing, trace element analysis, and micro- and
macroscopic analysis of bone tissue. Through these analyses, bioarchaeologists have been able to
detect and understand various health issues such as infectious diseases, various cancers, bone
abnormalities, issues such as obesity and diabetes, as well as many others.
Skeletal collections provide the greatest amount of biologically relevant information
about the past through bones, teeth, and occasionally hair. While rare in an archaeological
context, recovered hair samples may provide the bioarchaeologist a unique lens into the health of
past peoples through trace element analysis. This methodology, when conducted on wellpreserved hair samples, can provide an understanding of an individual’s health status at or
around their time of death. Although the literature pertaining to the bioarchaeology of health and
disease is plentiful, there is a lack of literature concerning neurological diseases in a
bioarchaeological context. While this is due in part to the rapid decomposition of the human
brain upon the moment of death, the preservation of other soft tissues permit bioarchaeologists to
study the human brain by proxy in skeletal collections.
Trace element analysis of hair equips researchers with the ability to assess elemental
profiles of hair to discern if an individual suffered from a neurological disease. An imbalance of
1

trace elements in the human body may be indicative of a variety of various diseases, one of
which is Alzheimer’s disease. Alzheimer’s disease is prevalent throughout the world with
roughly 5.4 million cases each year (Fisher et al., 2018). Alzheimer’s disease is characterized as
metal dyshomeostasis, an imbalance and/or breakdown of a relatively stable system, in this case
the brain, and has been defined as the progressive cognitive impairment of an individual due to
the formation of senile brain plaques (SBP) and neurofibrillary tangles (NFT) (Armstrong,
2013). These defining features have been regarded as the main pathological characteristics of
Alzheimer’s disease since its first description by Alois Alzheimer in 1907 (Armstrong, 2013).
Through hair analysis, researchers can view the indirect levels of toxic metals that may assist
with the progression of Alzheimer’s disease (Koc et al., 2015). Clinical studies have shown that
the study of hair allows researchers to study the abnormalities in brain trace element
concentrations, thus leading to possible diagnosis (Koc et al., 2015). Although there is an
abundance of clinical literature related to Alzheimer’s disease, there is no research concerning
the identification of this disease in past populations.
The aim of this study is to determine if Alzheimer’s disease can be detected in the
population recovered from the Kellis 2 cemetery in the Dakhleh Oasis, Egypt through the
analysis of preserved hair tissue. Identifying the presence of Alzheimer’s disease within the
bioarchaeological record at the Kellis 2 cemetery (50-350 AD) can allow anthropologists to gain
a better insight into the health of the population, while further analysis may allow us to
understand how Alzheimer’s disease was accepted and interpreted socially. Elemental analysis of
hair will be used to examine the presence of Alzheimer’s disease in the bioarchaeological record.
This research is imperative since the analysis of archaeological hair tissue using Inductively
Coupled Plasma Mass Spectrometry (ICP-MS) to identify the presence of neurological diseases
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has not been attempted before. The identification of Alzheimer’s disease in this context will help
researchers understand the longevity of the disease, specifically examining the depth of time for
its presence, and, detecting the presence of the disease in Kellis will allow us to understand how
it affected the lived experiences of individuals and groups, the medical treatments they received,
and the quality of life experienced.
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) will be used to conduct trace
element analysis of copper (Cu), aluminum (Al), zinc (Zn), manganese (Mn), iron (Fe), and
selenium (Se) within preserved hair samples from a cadaver sample (control sample) and a
bioarchaeological sample. These elements have been selected for analysis due to their prevalence
in the progression of Alzheimer’s disease (Atwood et al., 2002). The cadaver hair sample
consists of 13 adults from the Florida State Willed Body Program at the University of Central
Florida’s College of Medicine that have diagnostically confirmed or suspected Alzheimer’s
disease, and will serve as our control sample. The bioarchaeological hair sample consists of 11
adults (all with age estimates of 20+) and 2 juveniles from the Kellis 2 cemetery, Dakhleh Oasis,
Egypt. Once elemental profiles of both samples are created, a comparative analysis will be
conducted between the bioarchaeological sample and the modern cadaver sample to find possible
overlap between the two that may indicate the presence of Alzheimer’s disease in the population
of the Kellis 2 cemetery. Furthermore, a differential diagnosis of possible conditions that may be
conflated with Alzheimer’s disease such as Down Syndrome, Autism, Huntington’s disease,
Wilson’s disease, Amyotrophic Lateral Sclerosis (ALS), Prion disease, Epilepsy, mood
disorders, and Parkinson’s disease, will be conducted to allow for a greater probability of
accurately proposing the presence of Alzheimer’s disease in this sample.
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This research is centered on three questions: (1) What is the elemental profile of hair for
individuals with Alzheimer’s disease and how can we differentiate it from other neurological
diseases?; (2) Can we detect Alzheimer’s disease in the past through the examination of hair
tissue using ICP-MS?; and (3) Within the framework of the Bioarchaeology of Care theory, how
was Alzheimer’s disease and those affected by it perceived and/or cared for within their
community? I hypothesize that it will be possible to differentiate between Alzheimer’s disease
and Autism, Down’s syndrome, Wilson’s disease, Parkinson’s disease, prion disease, epilepsy,
mood disorders, amyotrophic lateral sclerosis (ALS), and Huntington’s disease through a
differential diagnosis. Furthermore, I hypothesize that Alzheimer’s disease will be present at the
Kellis 2 cemetery due to the prevalence of the disease in modern clinical literature as well as the
ancient Egyptian traditional medical literature.
The following chapters will investigate the hypothesis that Alzheimer’s disease can be
detected in the bioarchaeological record at the Kellis 2 cemetery in Dakhleh Oasis, Egypt.
Chapter 2 will provide an in-depth review of the literature regarding the Dakhleh Oasis, Kellis 2
cemetery, Alzheimer’s disease, hair structure and morphology, Ancient Egyptian medical
practices, the bioavailability of the six selected elements, ICP-MS and trace element analysis,
and the social theory being utilized for result interpretation. Chapter 3 will outline the
methodology, the materials used in this study, and the differential diagnosis. Chapter 4 will
present the results of the ICP-MS analysis for each trace element examined from the two samples
as well as the statistical analysis used to quantify the results from ICP-MS. Chapter 5 will
discuss determination of neurological disease within the represented Kellis 2 population.
Additionally, chapter 5 will also contextualize the results from ICP-MS into life experience in
Ancient Egypt, specifically concerning their medical treatments, medical practices, and the
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bioarchaeology of care index. Chapter 6 will conclude the study with a discussion of the final
results as well as future directions and limitations of the study.
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CHAPTER TWO:
LITERATURE REVIEW
To make a well-informed conclusion from this research, it's important to consider all of
the necessary background information. Therefore, the focus of this chapter is on the literature
concerning Alzheimer's disease, the archaeological site of origin for materials used in this study
and how hair has previously been utilized in bioarchaeological research. Following this will be a
review of ancient Egyptian neurology and medical treatments and practices specifically used at
Kellis. Lastly, a critical analysis of the bioarchaeology of care theoretical framework will be
explored with an in-depth review of the index of care created by Tilley in 2012.
To contextualize Alzheimer's disease in the past, it is necessary to understand the current
medical literature. This chapter will cover the basics of Alzheimer's neurochemistry, various
hypotheses for Alzheimer's development, and the disease demographic. Additionally, the
bioavailability of the six elements covered in this study will be assessed, with a thorough
contextual analysis of how the elements are absorbed within a biological organism, how the
elements are ingested today, as well as a contextual understanding of where these elements are
found in Ancient Egypt.
An understanding of the Dakhleh Oasis and Kellis 2 cemetery are required to elucidate
the daily lives of people living at the site to ascertain how their lives may have been impacted by
neurological degenerative diseases. Furthermore, it is necessary to investigate how neurology
was recognized and managed within Ancient Egyptian health care practices to understand how
individuals with Alzheimer's disease were cared for by medical professionals in the past. After
contextualizing the lives of past people within the Dakhleh Oasis and within Egyptian
neurological medical treatment, this chapter moves on to an examination of the methodology that
will be used in this study. The use of hair in archaeological analysis has the capability to provide
6

a wealth of knowledge and information to the researcher, which will be illuminated within this
chapter. Lastly, in order to contextualize this study, it's important to understand the theoretical
framework that will be used for this study. The bioarchaeology of care framework is a social
theory that examines how disabled individuals were cared for within a community, thus
strengthening community identity. This is pertinent to the central research questions because one
of the aims is to understand how individuals in the past with neurological conditions were cared
for. Have humans always gathered around their disabled loved ones? Was it normal, possibly
required, for individuals outside of the nuclear family to assist with the care of disabled
individuals within their community? The beginning of answering these questions lies at the heart
of the bioarchaeology of care framework.

Alzheimer's Disease
In 1907, Alois Alzheimer was the first to describe senile neurodegeneration (Alzheimer,
1907), which was then first called "Alzheimer's disease" by the pysician Kraepelin in 1910
(Armstrong 2013). Alzheimer's disease is now characterized by the presence of senile plaques,
neurofibrillary tangles, neuropil threads, amyloid beta-peptide deposition, and loss of neurons
coupled with decreased synaptic density (Lovell et al., 1998).
Alzheimer's disease affects roughly 5.4 million Americans aged 65 years or older, and it
is the fifth leading cause of death prior to COVID-19 in the U.S. (Fisher et al., 2018). Of these
5.4 million patients, 3.3 million (roughly 70%) are women in comparison to the 2.1 million (30%)
of men. Although researchers do not definitively know why women are more affected by
Alzheimer's disease, recent clinical studies have led to new hypotheses. Fisher et al. (2018) lists
these hypotheses as biological differences, including hormones, sex-specific genetic interactions,
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sexual dimorphism of neuroanatomy, difference in inflammatory response, and stress
interactions. Age remains the most significant risk factor for AD, and studies have shown that
the incidence of AD rises dramatically after the 6th decade of life. The APOE protein is
considered to be a risk-factor gene for Alzheimer’s disease (Bremner, 1999). In a study
conducted by Bremner (1999), women who had the APOE ε4 allele, a form of the APOE protein,
had Alzheimer's disease diagnosed five years earlier than men. Additionally, the odds ratio for
Alzheimer's disease in women with one copy of the APOE ε4 allele is four times greater than
men. Women carrying the ε3/ε4 allele tend to show a more rapid cognitive decline and
deterioration than men with the same allele (Fisher et al., 2018).
Senile brain plaques are extracellular deposits of amyloid-beta in the grey matter of the
brain. Brain plaques comprise degenerative neural structures that are created due to a wide array
of reasons, from AD to senescence (Miklossy et al., 1995). According to Miklossy et al. (1995),
senile plaques also called neuritic or argyrophilic plaques, are found in the cerebral cortex of
individuals with Alzheimer's disease. Senile plaques are complex, spherical structures, usually
100 to 150 μm in diameter, containing delicate argyrophilic filamentous structures, made of
neuronal and non-neuronal elements. Different components are usually described in conjunction
with senile plaques: degenerating neurites, neuropil threads, extracellular amyloid fibrils, and
reactive cells, including microglia and astrocytes. Neurofibrillary tangles are formed by
pathological argyrophilic filaments accumulated in the neurons' cytoplasm, often extending into
the apical dendrite. Neuropil threads, also called "curly fibers" or argyrophilic filamentous
structures, are slender silver-stained structures measured at 100 μm thick found in senile brain
plaques.
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Various forms of AD have been associated with mutations in either the amyloid precursor
protein (APP) for cortical amyloid (Aβ) or presenilin-1 (PS1) or presenilin-2 (PS2) (Murphy &
LeVine, 2010). Aβ is a by-product of the amyloid precursor protein gene (APP), which is divided
into two endoprotease activities, β- and γ-secretase. Aβ42, a slightly longer form of Aβ, is the
main form of protein that is deposited in the brain during the development of Alzheimer's disease
(Murphy & LeVine, 2010). Aβ has been described as causing various deleterious effects in the
brain by triggering processes that occur independently of Aβ deposition (Figure 1). According to
Murphy and LeVine (2010) Aβ has shown a direct involvement in disrupting neural connectivity,
synaptic dysfunction, and neuronal death.

Figure 1: In Alzheimer’s disease, levels of Aβ 1-42 are low, while amino acid form of tau protein,
phosphorylated tau protein, and neurofibrillary tangles are increased (Modified from Barichello
et al., 2019).
Although the acceleration of aging and brain degeneration are plausible hypotheses for
the development and progression of Alzheimer's disease, researchers have found strong evidence
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supporting environmental factors influencing the progression of Alzheimer's disease. These
environmental factors include aluminum, copper, zinc, iron, selenium, and manganese (Hammer
et al., 1971; Bolognin et al., 2009; Greenough et al., 2013; Armstrong, 2013).

Bioavailability of Elements
Bioavailability is defined as the total amount of a chemical present in ingested food,
water, soil, and sediment particles released during digestion (Peijnenburg & Jager, 2003).
Bioavailability is a dynamic process and is comprised of two distinct phases. Phase one is a
physiochemically driven desorption process, while phase two is a physiologically driven uptake
process, requiring the identification of specific biotic species as endpoints (Peijnenburg & Jager,
2003). Once the present chemical has been ingested, it becomes bioaccessible, meaning that it
can be transported across the intestinal wall and accumulate in the lymph or bloodstream. Then,
compounds that were absorbed by the body are transformed and excreted in either the liver or the
intestinal epithelium. This is known as the first-pass effect, followed by the chemicals being able
to freely circulate throughout the body (Peijnenburg & Jager, 2003).

Aluminum (Al)
Aluminum is the third most abundant element on earth after oxygen and silicon and has
been studied as a neurotoxin (Tomljenovic, 2011). Aluminum (Al) has no biological essentiality
and appears to be poorly excreted from the body. Regarding Alzheimer's disease, aluminum is
one of the only trace elements recorded to trigger all major histopathological events of the
disease (Crapper et al., 1973). Aluminum has been shown to decrease cognitive and psychomotor
performance in humans and animals, impair visuomotor coordination, long-term memory, and
long-term hippocampal potentiation (Tomljenovic, 2011). Furthermore, aluminum reduces
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various neurotransmitters' activity levels, such as acetylcholine, serotonin, norepinephrine,
dopamine, and glutamate. Finally, aluminum has been shown to damage dendrites and synapses
in the brain, inhibit glucose utilization in the brain, and reduce glucose uptake by cortical
synaptosomes (Tomljenovic, 2011).
Environmental aluminum is very accessible for humans to absorb regularly, and it is
common for aluminum to accumulate in brain regions that are positively affected by Alzheimer's
disease pathology. Crapper et al. (1973) outlines these regions as the entorhinal cortex,
hippocampus, and the amygdala. The areas associated with a higher cognitive function such as
the basal forebrain cholinergic neurons, pyramidal cells in the hippocampus and the cortex and
upper brain stem catecholaminergic neurons are the most affected in Alzheimer's disease
(Tomljenovic, 2011).
Aluminum is toxic to mammals in high amounts; however, the consensus is that Al is not
required for proper functions within biological systems (Fulton et al., 1989). Aluminum is found
in drinking water at levels between 0.031 and 0.112 mg/L, with maximum Al concentrations of
about 2.7 mg/L. A primary source of Al in processed foods is found in the form of sodium
aluminum silicate (Reiber et al., 1995). Additionally, Al is commonly found in drinks such as
brewed tea and coffee, which generally contain between 300 and 1,000 μg/L of Al (Reiber et al.,
1995).
In ancient Egypt, traces of Al, measured in % by weight, was found in papyrusat 4.50%,
which is the third highest element recorded in ancient papyrus next to oxygen and carbon at
38.58% and 36.22% respectively (Wiedeman & Bayer, 1983). El Agami et al. (2005) report that
there are large amounts of aluminum-phosphate minerals within Egypt’s Western Desert, and
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would have potentially been an environmental sources of Al exposure for the inhabitants of
Kellis.

Copper (Cu)
Copper is known to play a role in Alzheimer's disease's pathogenesis. Copper is an
essential element and is required for multiple biological processes such as energy production by
the cytochrome c oxidase enzyme, in which copper is tightly bound at specific sites to the protein
(Faller, 2012). While an essential nutrient for humans, a recommended dietary allowance has not
been established (Turnlund, 1988). Several physiological roles for Cu in humans have been
suggested, including cross-linkage of connective tissue, skeletal mineralization, myelin
formation, oxidation of ferrous iron, antioxidant protection, and many more. Foods high in Cu
include organ meats such as the liver and kidneys, some cereals, fruits and nuts, while foods low
in Cu include milk and dairy products. In a study by Lönnerdal (1996), it was noted that the
absorption of Cu was higher in individuals who had an animal-protein diet in comparison to
individuals with a plant-protein diet. However, although the Cu content from the plant-protein
diet was much lower, the Cu ingested was absorbed more effectively than the individuals with
the animal-protein diet.
Faller (2012) cites many in vitro and in vivo studies reporting a connection between
Alzheimer's disease and copper metabolism. Although these studies show a definite connection
between copper and Alzheimer's disease, it is unclear if Alzheimer's disease is a by-product of
copper overload or copper deficiency. Researchers have argued that Alzheimer's disease could be
a copper-overload disease, much like Wilson's disease, while other researchers such as Speziali
et al. (2013) argue that the connection is inconclusive. There are reported increases in labile
copper pools in human brain regions affected by Alzheimer's disease compared to regions
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relatively unaffected by the disease (Faller, 2012). This suggests that the regions with labile
copper pools are responsible for creating oxidative stress in the brains of individuals with
Alzheimer's disease. Faller (2012) hypothesizes that it is thought that the labile copper pool in
brain regions affected by Alzheimer's disease increases at the expense of the copper bound to
proteins in the region. Sparks and Schreurs (2003) report that adding 0.12 ppm (parts-per million)
of copper to drinking water increased the risk of developing AD due to the deleterious effects
copper has on the brain. The U.S. Environmental Protection Agency allows 1.3 ppm of copper in
human drinking water, which is over ten times the toxic amount recorded in the 2003 AD study
conducted by Sparks and Schreurs. These data indicate that this is one avenue for why
individuals are becoming more exposed to inorganic copper, thus increasing the amount of
Alzheimer's disease cases per year.
In ancient Egypt copper was extracted from mines, as confirmed by mining settlements
and inscriptions at sites such as Magharash dating back to the Middle and Old Kingdom (27001782 BC) (Lucas, 1927). Large amounts of copper ores have been detected in Sinai and both the
Western and Eastern deserts. Medically, copper was used to sterilize daily drinking water and to
sterilize wounds (Borkow & Gabbay, 2009), and to help fight off trachoma, as disease of the eye
caused by Chlamydia bacterium (Sipos et al., 2004). During the Roman occupation of Egypt,
copper cooking utensils were regularly used to prevent the spread of various diseases. As part of
their beauty rituals, ancient Egyptians also used copper silicate, which gave off a blue-green
color, as an eyeshadow (Borkow & Gabbay, 2009).

Zinc (Zn)
Zinc is among the most researched trace elements in connection to Alzheimer's disease
pathogenesis. It has been suggested that low serum zinc levels are responsible for the progression
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of Alzheimer's disease (Haines et al., 1991). A study conducted by Craddock et al. (2012)
suggests that the reduced intra-neuronal zinc levels are caused by the sequestration of zinc by βamyloid deposits (Aβ oligomers and plaques). Craddock et al. (2012) also reported that
insufficient zinc may trigger GTP (guanosine triphosphate) hydrolysis and MT (microtubule)
catastrophes, which then induce NFT formation and cognitive impairment.
Lovell et al. (1998) found a zinc enrichment of senile plaques in the brains of individuals
affected by Alzheimer's disease and also reported an elevation of zinc in the neuropil of AD. It is
thought that zinc levels may contribute to the depletion of β-amyloid, giving rise to unstructured
aggregates that increase Aβ neurotoxicity (Bolognin et al., 2009). Bolognin et al. (2009) report
that the interaction between zinc and Aβ also reduces zinc availability in the synaptic cleft. This
can lead to detrimental effects regarding the role of zinc in neuronal signaling and synaptic
plasticity.
Due to the nature of Zn as a transitional element in the periodic table it possesses specific
chemical properties that make it especially useful and essential in biological systems (Brown et
al., 2001). Myoinositol hexaphosphate (phytate) is a major inhibitor of Zn absorption and can be
found in many non-processed plant foods such as cereals and legumes as well as fermented foods.
Ideal sources of zinc are organs and animal tissue since they do not contain phytate; however,
dairy products such as eggs contain the lowest amount of Zn. Fruits have very minimal amounts
of Zn for absorption, while leafy green vegetables such as spinach have relatively high Zn
density (Brown et al., 2001).
There are not a lot of instances of Zn being used regularly in ancient Egypt except for its
use as a medicinal cream to heal wounds and repair skin (Frederickson et al., 2005). In addition,
it was also used by women as a face cream to try to keep their youthful glow. This is now known
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as calamine cream and it has been used in ancient Egypt since roughly 2000 B.C. (Frederickson
et al., 2005).

Iron (Fe)
The clinical literature associated with Alzheimer's disease reports an increase in iron
levels and iron-binding proteins in the brains of individuals affected by AD. It is thought that
increased heme oxygenase activity, caused by oxidative stress in the brain, could trigger
increased iron levels (Bolognin et al., 2009). Furin is an enzyme whose proteolytic activity is
needed for various cellular processes, and it is thought that iron influences the production of Aβ
through its interaction with furin. It is believed that iron minimizes furin activity, which in turn
minimizes α-secretase activity favoring β- and γ-secretase activity with the consequent
enhancement of Aβ production. Through its interaction with iron, furin mRNA levels were
decreased in patients with AD (Gonzalez-Dominguez et al., 2014). The iron metabolism found in
patients with AD is derived from genetic and protein-related factors such as over-expression of
melanotransferrin (MTf), hemochromatosis protein (HFE) mutation, or the decreased ability of
ferritin to retain iron (Gonzalez-Dominguez et al., 2014).
Physiologically, iron is absorbed by two separate pathways, 1) heme iron, derived mainly
from hemoglobin, and 2) non-heme iron (Fairweather-Tait, 1992). While non-heme iron is
present in animal tissues and plant foods, heme iron is thought to add roughly 15% of total Fe
intake in meat-eating populations. While there are many Fe inhibitors found within everyday
foods, including ascorbic acid-containing vegetables, phytate found in plant based foods is the
primary inhibitor of Fe absorption. A second Fe inhibitor is polyphenol, which is found in
vegetables, fruits, cereals, legumes, tea, coffee, and wine (Fairweather-Tait, 1992). .
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Iron was one of the most common elements found in ancient Egypt as meteorites are
ubiquitous throughout the Egyptian landscape (Wainwright, 1932). Archaeological evidence
shows that ancient Egyptians took advantage of these meteorites and used the iron within them
for manufacturing items such as weapons, cooking utensils, jewelry, and many more (Johnson et
al., 2013). Additionally, iron was often mixed with red ochre and used in makeup such as eye
paints and cheek coloring (Froment et al., 2008).

Selenium (Se)
Studies conducted on humans confirm selenium's participation in the pathogenesis of
brain disorders, either isolated or in combination with other elements (Santos et al., 2014).
Smorgon et al. (2004) described a direct correlation between reduced selenium plasma
concentrations and cognitive function decline in patients with Alzheimer's disease. Varikasuvu et
al. (2019) show that selenium distribution within the brains of individuals with Alzheimer's
disease is heterogeneous between the different regions; however, decreased selenium levels were
found at the temporal, hippocampal, and "other" subgroup, while increased selenium levels were
found in the amygdala. Selenium is an antioxidant that incorporates selenoproteins such as
selenoprotein P (SelP), glutathione peroxidase, and thioredoxin reductases into brain tissue. Due
to the decrease in selenium level in patients with AD, there is less antioxidant defense to protect
the brain, leading to impaired brain and cognitive functions in patients with AD (Varikasuvu et
al., 2019).
High amounts of Se is toxic to biological organisms and may cause the mutagenesis of
cells. Just as with any other trace element, there is a "safe range" for Se levels in a biological
organism, and anything outside of that range may bring about disease or toxicity (Young et al.,
1982). Although the requirements for Se intake have not been established, the U.S. Food and
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Nutritional Board has concluded that for healthy adults, the daily intake of Se should
approximate roughly 50 to 200 μg. Se is present in most foods, but published estimates of human
daily intake reveal a relatively wide range of ingested Se. Bioavailability of Se is impacted by
various factors, including food processing and preparation; however, cooking appears to result in
little significant loss of Se in most foods. In animal protein, Se is present as selenocysteine,
selenomethionine, selenotrisulfide, and selenopersulfides (Young et al., 1982).
There were not many sources of selenium found within ancient Egypt, only low levels
found in the floodplain soil of the Nile River and relatively low amounts of selenium within
various foods (Moatkhef et al., 2020). Analysis has shown that there were relatively low levels of
selenium found within local Egyptian fruits such as dates, grapes, and figs. Additionally, there
are relatively low levels of selenium found within the local nuts and seeds such as fenugreek,
however sesame seeds have a very high content of selenium. Additionally, selenium levels were
found to be very low in rice and local bread, while protein rich foods such as fish were found to
have the highest levels of selenium (Moatkhef et al., 2020).

Manganese (Mn)
The final trace element considered in the pathogenesis of Alzheimer's disease is
manganese. Manganese is often found in drinking water and is believed to have neurotoxic
potential (Dieter et al., 2005). Manganese can destroy the human dopaminergic receptors in the
brain, inhibit the expression of F1ATPase in the globus pallidus, and cause oxidative disturbance
of dopamine metabolism. It is believed that the increase in brain manganese levels in individuals
with Alzheimer's disease may be due to the overexpression of the APP gene (Dieter et al., 2005).
Dumont et al. (2009) found that the manganese superoxide dismutase enzyme located in the
mitochondrial matrix increased amyloid deposition and tau phosphorylation in transgenic AD
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mice. The study conducted by Dumont et al. (2009) concluded that manganese has a role in the
pathogenesis of Alzheimer's disease; however, more research is necessary to understand its exact
interaction with the brain environment.
Manganese is an essential nutrient for humans and animals; however, in excessive
amounts, manganese is also a toxic substance (Kies, 1987). Plant-based foods such as tea, cereals,
nuts, and dark leafy vegetables contain high amounts of Mn; However, they often have traces of
tannins, oxalates, phytates, and fibers have been documented to inhibit the absorption of Mn.
Animal products such as milk, eggs, red meats, fish, and poultry are known to have low amounts
of Mn; however, the absorption of Mn is more effective on an animal-protein diet in comparison
to plant-based diets (Kies, 1987).
Black oxide of manganese was used regularly in ancient Egypt as both makeup and
paint. . Analysis of kohl from ancient Egypt, a form of make-up used to line the eyes (Badeeb et
al., 2008), revealed it was primarily composed of manganese, copper, and iron. Manganese is
also found in the paint on many ceramics found in ancient Egypt (Noll, 1981).

Behavioral Alterations of Alzheimer’s Disease
Alzheimer’s disease is a neurological disturbance that affects the intangible mind in
tandem with the physical alterations of the human brain. Throughout the years, researchers have
attempted to grapple with the clinical realities of the behavioral changes that accompany this
disease. Identifying and understanding the behavioral changes that accompany the progression of
Alzheimer’s disease is necessary because behavioral disturbances are associated with greater
caregiving burden, a shorter time to nursing home relocation, and a greater cost of patient care
(Cummings et al., 2008). If we are to examine the individual and communal impact that
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Alzheimer’s disease had on caregiving within the Dakhleh Oasis, it is paramount to understand
the behavioral disturbances associated with this disease.
According to Cummings et al. (2008), individuals with advanced Alzheimer’s
progression require increased staff/caregiver commitment, supervision, and medication use.
While researchers have been able to gather some data regarding the behavioral alterations of
patients with Alzheimer’s, there have been impediments to the continued understanding of these
disturbances due to the lack of clear operationalized definitions of behaviors, general absence of
data regarding behavioral changes in relationship to AD treatment, and a less than clear
understanding of the physiological changes that implement the behavioral disturbances (Mega et
al., 1996).
Ideally, it would be beneficial to have a set template of behavioral disturbances
associated with Alzheimer’s disease, however human behavior can rarely be accurately
predicted. Instead, researchers have created lists dedicated to general behavioral patterns
associated with Alzheimer’s patients, both advanced and mild. According to Mega et al. (1996),
one of the earliest signs of behavioral changes associated with AD is a change in personality that
most commonly includes apathy and disengagement. Apathy is more notable in patients with AD
than depression and is usually seen more commonly within patients of an older onset age.
Additionally, agitation is listed as a common behavioral disturbance within AD patients which
includes abnormal motor behaviors, verbal abuse, and physical aggression. Lastly, Mega et al.
(1996) note that delusions affect 10-37% of AD patients, with elation at 5-17%, wandering at 1061%, assault of others at 18-65%, and hallucinations at 3-50%.
Caregivers have experienced many behavioral disturbances associated with Alzheimer’s
patients that include changes in neuroticism, extrovertism, openness, and agreeability (Chatterjee
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et al., 1992). This study found that caregivers were responsible for handling AD patients who
became more neurotic, anxious, and depressed. Additionally, patients were seen has being less
agreeable, less conscientious, and less open with their caregivers. While some psychiatric
symptoms included dysphoria and depression, AD patients were also noted as developing more
intense imaginations (Chatterjee et al., 1992).
A very interesting study conducted by Ott et al. (1996) investigated the role of sex in
relation to AD behavioral disturbances. Previous studies have noted a relationship between
specific behavior disturbances and sex based on the assessment of caregivers. For example, it is
noted that males with AD are significantly more aggressive, have an unorthodox obsession with
bodily function, and a significant loss of interest in daily activities. Additionally, males were
found to be more sexually aggressive than females with AD. To test whether sex affected the
presentation of AD behavioral disturbances, Ott et al. (1996) examined 125 individuals with AD
(50 males and 75 females) with reliable and thorough caregiver information. Their study found
no significant difference between the overall severity of behavioral disturbances of males and
females with AD; however, they did find that there is a sex influence regarding the qualitative
facets of the behavioral disturbances. For example, females were found to be more emotionally
unstable and isolated, tending to refuse help from caregivers, while males were found to exhibit
changes more closely related to psychomotor function, particularly aggression (Ott et al., 1996).

Ancient Egyptian Healthcare and Medicine
One of the oldest cultures with medical literacy is that of ancient Egypt – the birthplace
of neuroscience (Stern, 1989). Egyptian medicine was a mixture of rational, magical, and
religious elements (York & Steinberg, 2009). Egyptian physicians used a combination of
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medications, physical manipulation, prayers, and incantations to treat their patients (York &
Steinberg, 2009).
Although ancient Egypt had a vast medical history, much of the medical literature has
been lost. The Ebers Papyrus, named after its first modern owner, the German Egyptologist
George Ebers, details explanatory elements to treat a variety of internal illnesses (Janssen &
Janssen, 1996). Conversely, the Edwin Smith Papyrus, named after an American dealer who
acquired it, details more traumatic injuries sustained in battle and how they were handled by
Egyptian medical professionals (Janssen & Janssen, 1996). The Ebers Papyrus and the Edwin
Smith Papyrus are only two of the major sources of ancient Egyptian literature that researchers
have been able to recover and translate, which has allowed modern researchers to reconstruct and
evaluate many ancient Egyptian medical practices.
There was little distinction between magic and religion in ancient Egyptian medicine
(Nunn, 2002). It was believed that diseases were either due to evil spirits or the wrath of the gods
(Okasha & Okasha, 2000). More specifically, supernatural beings called "disease demons" were
said to have controlled the causation of disease (Nunn, 2002). In the case of trauma and/or
external wounds, individuals would opt for conventional treatment through a physician;
however, in the case of an internal disorder with an unknown etiology, the outcome was
uncertain, and individuals would turn to magic for help (Nunn, 2002). Additionally, Nunn (2002)
explains that people in ancient Egypt turned to the gods for help, both at home and in medical
centers, with their ailments due to the cost, risk, uncertainty of outcome, discomfort, and
physical pain of ancient treatments by medical professionals. Expectations of a cure and
beneficial effects from magic and pronouncement of an incantation have been documented in the
ancient Egyptian medical texts, known today as the placebo effect (Nunn, 2002).
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Ancient Egyptian physicians relied heavily on plants and herbs for their therapeutic
value. Many of the plants and herbs gathered and used by the ancient Egyptians had high
alkaloid content, thus heightening their therapeutic value (Nunn, 2002). Nunn (2002) explains
that for a plant or herb to have the highest potential of efficacy, the preparation must be related to
the time of day that the plant is gathered; however, many scholars have attributed this
preparation to heightening the placebo effect in the patient since there is no rational benefit to
this practice other than increasing the expectation of a cure. Additionally, the practice of
selecting a herbal remedy from a plant was aligned with its resemblance to the organ requiring
treatment, also called similia similibus (Nunn, 2002).
The most notable tools used by ancient Egyptian healthcare professionals, aside from
herbal remedies, include magic, incantations, and amulets (York & Steinberg, 2009).
Incantations are a series of words said as a magic spell or charm recited by a magician (York &
Steinberg, 2009), and in ancient Egypt, most incantations were intended to be used jointly with
an herbal remedy provided by a healthcare professional (Nunn, 2002). Nunn (2002) explains that
the act of taking herbal medicines while a magician recited an incantation over the sick or injured
was widespread in the ancient world and continued for thousands of years. It was believed that
knowing someone's name, particularly their secret name given at birth, gave power to the
individual reciting the incantation and increased the likelihood of recovery (Nunn, 2002).
In addition to incantations, amulets were also used by healthcare professionals and
magicians in ancient Egypt. Amulets allowed for the preservation and protection of the body in
both life and death (Nunn, 2002). According to various medical papyri, there are three types of
amulets used by the ancient Egyptians; (1) homopoeic amulets which portrayed living creatures
from which their wearer hoped to assimilate their desirable attributes; (2) phylactic amulets
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which were used to protect individuals from malign spirits; and (3) theophoric amulets which
represented Egyptian gods and allowed the wearer to gain the strength or help that they needed
from the particular god associated with the amulet they chose to wear (Nunn, 2002).
Medical treatments in ancient Egypt are not far removed from what we see in today's
modern society. Each physician had a single specialty and no other (Martin-Araguz et al., 2002).
For example, some doctors were responsible for curing diseases of the eye, some of the head,
some of the intestines, etc. (Martin-Araguz et al., 2002). Additionally, the diagnosis process used
by ancient Egyptian medical professionals is very familiar to that of modern medical
professionals. For example, Austin (2014) outlines the medical process in ancient Egypt from a
patient's initial contact with a doctor through to the aftercare stage (Figure 2). The first step is an
examination of the patient by the doctor, followed by diagnosis and prognosis, then by treatment,
whether done by herbs, magic, amulets, etc. Finally, the aftercare stage determines if the patient
is cured or if steps 2-4 need to be repeated (Austin, 2014).
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Figure 2: The medical process of a patient’s interaction with a medical professional in ancient
Egypt (Modified from Austin, 2014)
Since the majority of physicians of ancient Egypt specialized in one area of the body, it is
not surprising that it is the birthplace of neuroscience (Vatanabe et al., 2020). Although it is
unclear if the ancient Egyptians had a medical understanding of the nervous system, it appears
that they still had an anatomical concept of it which they referred to as metu (Martin-Araguz et
al., 2002). Metu is thought to be the first rudimentary concept of the nervous system, and it was
used to refer to the idea that the body consisted of a system of channels that communicated with
one another (Martin-Araguz et al., 2002). In the Ebers papyrus, these channels or vessels are
described in a likened similarity to the hydraulic channels that branch from the Nile River and go
from the limbs to the head and/or the heart (Martin-Araguz et al., 2002).
Although no definitive writings describe medical professionals that were devoted to the
nervous system, there is documentation describing specialists of the head (York and Steinberg,
2009). Specialists of the head were knowledgeable about the skull as well as the human brain,
and that ancient Egyptians were among the earliest to label the various bones in the human skull
for medical purposes (York & Steinberg, 2009). The word djennet refers to the whole of the
human skull, the occipital bone is referred to as ha, the zygomatic arch is called gema, and the
parietal bone is called paqyt (York & Steinberg, 2009). A detailed diagram of the skull labeled
with hieroglyphs can be found in Figure 3.
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Figure 3: Lateral aspect of the human skull with Egyptian words for different parts of the head
(Modified from Karenberg & Leitz, 2001).
The ancient Egyptian word for the brain is ais; however, although they had a word for the
human brain, it does not directly imply that they have a firm understanding of its function (York
& Steinberg, 2009). Although theories of the brain's function are possibly unfamiliar to the
ancient Egyptians, they continued physical examinations of it and further postulated its possible
functions.
In both the Edwin Smith Papyrus and the Ebers Papyrus, the brain is described as a result
of open cranial trauma as being hemispheres patterned with "convolutions” and enclosed in a
membrane (Nasser, 1987). They further liken the external appearance of the brain to the
corrugations arising in metallic slag (Okasha and Okasha, 2000). Although scholars have debated
if the ancient Egyptians had a true understanding of the brains function, it is detailed in the Ebers
Papyrus that they believed the brain was the site of mental function and emphasized the
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importance of assessing the consciousness and memory of patients in all routine medical
examinations (see Table 1 for descriptive terms noting possible neurological issues) (Nasser,
1987). The earliest record of recognized neurodegenerative conditions originated in ancient
Egypt in roughly 3,000 B.C. when Prince Ptah-Hotep described senile deterioration, which was
one of the first neurological descriptors of human aging (Vatanabe et al., 2020).
Table 1: Descriptive quotes from the Ebers Papyrus (denoted by “Eb.”) detailing possible
neurological issues identified by medical professionals
Original Source

Descriptive Medical Texts

Eb, 855

"As to the mind kneeling in the
interior of his belly, the purulency
falling on his heart"
"To expel 'aaa' poison from the heart,
expel fleeting forgetfulness and
injury to the mind"

Eb. 277

Possible Diagnosis and Recent
Source
Suggests a possible degradation of
thinking (Okasha & Okasha, 2000)
Suggests a possible reference to
what we now call dementia
(Okasha & Okasha, 2000)

Eb. 855

"The perishing of the mind (ib)"

Possibly referring to dementia or
Alzheimer's disease (Nasser, 1987)

Eb. 855

"The mind (ib) is forgetful like one
who is thinking of something else"

Diagnosis unavailable (Nasser,
1987)

Eb. 227

"The fleeting mind (ib)"

Eb. 227

"His mind (ib) goes away"

Diagnosis unavailable (Nasser,
1987)
Possibly referring to dementia or
Alzheimer's disease (Nasser, 1987)

Eb. --

"As to perishing of the mind and
forgetfulness; it is the breath of the
activity of the reciting priest that does
it. The breath enters into the lungs
several times, and the mind becomes
confused by it"

Possibly a description of dementia
or Alzheimer's disease –
specifically vascular dementia
(York & Steinberg, 2010).

Eb. --

"Suffers in his mind and his fingers
tremble"

A possible reference to Parkinson's
disease (York & Steinberg, 2010).

The ancient Egyptians also believed that the activities of the brain were linked directly to
internal organs such as the liver, heart, lungs, etc. (Vatanabe et al., 2020). Furthermore, medical
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professionals believed that although organs were linked to the brain, they believed that brain
disorders were linked primarily with the heartbeat (Martin-Araguz et al., 2002). Doctors during
this time believed that the frontal lobe of the brain was a secret chamber or the sanctuary of a
temple for the gods (Martin-Araguz et al., 2002).

Medicine in Greco-Roman Egypt
Records of medical treatments and care systems are minimal to non-existent for the site
of Kellis. This requires researchers to rely on general medical texts from the Romano-Christian
occupation of Egypt. We know there were many people at Kellis with skeletal injuries and
pathologies through osteological analysis; however, it is not certain what kind of health care
system was in place due to lack of text from the area. Hasan (2017) explains that Roman
occupied Egypt (30 BC - 641 AD) had both government and private doctors. These physicians
could be any Greek, Roman, or Egyptian man with the proper medical training. Hasan (2017)
also explains that hospitals during this time were widespread throughout the country – both
private and government institutions. The origin of private independent hospitals within Roman
Egypt can be traced to roughly the third century (Hasan, 2017).
The skeletal pathological conditions identified on the individuals from the Kellis 2
cemetery indicate that individuals within this community suffered from many health issues, such
as cancer, tuberculosis, leprosy, broken and fractured bones, and various traumas. To deal with
these issues, we can assume they would require a system of care as they could not work, walk, or
carry on with basic daily activities. While these pathological conditions are not relevant to
neurological health or neurodegenerative diseases, they provide evidence that medical treatment
and health care institutions were established to assist those with various ailments. This
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information is necessary to assess whether individuals with neurodegenerative diseases at Kellis
would receive medical care and treatment.

The Dakhleh Oasis
The Dakhleh Oasis is one of the seven major oases in Egypt. The Dakhleh Oasis is a
depression located in the Western Desert of Egypt, extending more than 80 km east/west and
approximately 30 km from north/south (Figure 4) (Dupras et al., 2001) and positioned roughly
800 km south-west of Cairo (Hope & Hope, 1988). The oasis has been known to the western
world since Sir Archibald Edmonstone visited in 1819, but the Dakhleh Oasis itself was not
explored until the late 20th century (Boozer, 2013). The archaeological evidence for human
activity in the region during the Roman occupation is plentiful (30-400 BCE) and shows that the
Dakhleh Oasis is ideal for studying daily life in Roman Egypt. The presence of water derived
from the Artesian-water sandstone underlying the oasis makes it possible for individuals to
inhabit the region (Boozer, 2013).

28

Figure 4: Map showing the location of the Dakhleh Oasis in relation to its surroundings
(Modified from Williams, 2008).
Dakhleh's hospitable lands have allowed for continuous human activity extending from
the lower Paleolithic to the present day (Dzierzykray-Rogalski, 1980). Although there is a large
distance between Dakhleh Oasis and the Nile Valley, throughout the Dynastic Egyptian period,
Dakhleh was known as a fertile land where goods such as olives, dates, and wine were produced
until the Roman occupation (Boozer, 2013). The Kellis Agricultural Account Book has been
used by researchers to understand the human activity in the Dakhleh relating to sustenance
practices during the Romano-Christian occupation. From this text, researchers have a good sense
of the field and fruit crops used during this time (Boozer, 2013). The predominant form of wheat
grown was triticum aestivum and other common crops included hay, sesame, turnips, dried figs,
dates, olives, and cotton (Boozer, 2013).
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The climatic conditions of the region are severe and made daily life difficult. The average
rainfall in Dakhleh is roughly 0.7 mm per year (Adelsberger & Smith, 2010), and although
minimal, this rainfall is vital to the survival and maintenance of populations living within the
boundaries of the Oasis (Kleindienst et al., 1999). Winter temperatures ranged as low as 0-2
degrees Celsius, while in the summer the temperatures reached 40 degrees Celsius (Boozer,
2013). From approximately the first to fourth century AD, the Romans occupied the Dakhleh
Oasis, which has retained a wealth of well-preserved human and material remains from the
period. This period is referred to as the "Romano-Christian Period" and it is believed to have
dissipated roughly towards the end of the fourth century AD (Boozer, 2011).

Kellis 2 Cemetery
The site of Kellis, also referred to as Ismant el-Kharab by modern locals, was a
settlement that housed several thousand people by the fourth century AD and was an important
political and economic center in Dakhleh Oasis ((Hope & Hope, 1988). Kellis was an important
epicenter of activity in Egypt's Dakhleh Oasis for several centuries during the Ptolemaic and
Roman Periods (30-400 BCE) (Molto, 2002). The settlement is flanked by two cemeteries
identified as Kellis 1 (West) and Kellis 2 (East). The Kellis 2 cemetery is located to the NorthEast of the Kellis settlement (Bowen, 2003), and dates mainly to the 3rd and 4th centuries A.D.
which would associate the site with the later Roman Period, and early Christian occupants
(Molto, 2002). In the Roman Period, the population of Dakhleh Oasis, specifically Kellis, may
have increased substantially. However, the population size and density were still small and the
villages, like today, were widely spaced (Molto, 2002).
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Burials within the Kellis 2 cemetery consist of well-preserved, mostly single interments
with bodies oriented east-to-west with the head placed at the west and the body in an extended
position (Dupras et al., 2016). The arid conditions of the area have provided the ideal climate for
excellent skeletal and soft tissue preservation (Figure 5; Figure 6). Approximately 770
individuals have been recovered from the Kellis 2 cemetery (Figure 7); however, it is estimated
that the cemetery contains up to 4,000 burials (Dupras et al., 2001). The recovered population of
Kellis 2 is comprised of all age groups, making it an excellent site for demographic studies. It’s
believed that all members of the Kellis population were buried at the Kellis 2 cemetery, except
for non-Kellis residents. The mortuary pattern of the excavated section of Kellis 2 is random,
meaning individuals of both sexes and of all ages have an even probability of being exhumed
(Molto, 2002).

Figure 5: Example of preservation of hair and skin on individuals from Kellis 2 Cemetery
(Modified from Sharman, 2007).
The demographic for the Kellis 2 cemetery can be found in Table 2. A total of 724
individuals have been recovered to date, with 64% juveniles and 36% adults (Dupras et al.,
31

2016). Of the juveniles recovered from Kellis 2, those aged 0-12 months are the most
represented at 24.5%, while those aged 11-15 years are the least represented at 3.1%. These
numbers reflect the high infant mortality rate for this site. The high infant mortality is supported
by the higher percentage of juveniles found at the site in comparison to adults. Table 2 also
shows a higher proportion of adult females (21.2%) at Kellis 2 than adult males (14.5%), with
only three remaining adult individuals of an unknown sex (Dupras et al., 2016).

Table 2: Demographic information of individuals from Kellis 2 cemetery (Modified from Dupras
et al., 2016).
Number

Percentage

Sex Information
Male
Female
Adult of Unknown Sex

105
153
3

14.5 %
21.2%
0.4%

Age Information
Fetal
0-12 months
1-4 years
5-10 years
11-15 years
Juveniles of Unknown Age
16-35 years (young adult)
36-50 years (middle adult)
51+ years (old adult)
Adults of Unknown Age
Total Juvenile
Total Adult
Total

106
178
102
47
22
8
128
79
51
3
463
261
724

14.6%
24.5%
14.2%
6.5%
3.1%
1.1%
17.6%
10.9%
7.1%
0.4%
64%
36%
100%

Paleopathological studies conducted at the site provide evidence of many skeletal
pathological conditions throughout the population. For example, Dupras and Cope (2011) note a
fetal individual found in the Kellis 2 cemetery with osteogenesis imperfecta (OI), also known as
brittle bone disease. Donoghue et al. (2005) notes having found individuals at Kellis 2 with
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Mycobacterium leparae and Mycobacterium tuberculosis. Within the greater Dakhleh Oasis,
Egypt, Molto and Sheldrick (2018) reference 6 cases of cancer, including testicular cancer,
cervical cancer, and breast/ovarian cancer. Specifically, within Kellis 2, Molto and Sheldrick
(2018) estimated individual K2-219 died from acute lymphocytic leukemia, while K2-714 is
believed to have died from metastatic carcinoma. Furthermore, Sheldrick (2020) reports many
traumatic injuries found at Kellis 2, including Colles fracture (K2-B202), femoral head fractures
in 17% of post-menopausal women, various debilitating leg fractures, “boxer” fractures (K2-B9),
shaken baby syndrome (K2-B519), and a dagger wound in left ribs (K2-B227).

Figure 6: Example of excellent preservation of skeletonal material from Kellis 2 Cemetery
(Modified from Molto and Sheldrick, 2018).
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Figure 7: Map of Kellis 2 cemetery in the Dakhleh Oasis. Burials used in this study are identified
with a red circle (Modified from Williams, 2008).
All of the graves at Kellis 2 are aligned on an East-West axis with minor deviations that
may reflect the winter or summer burials (Williams, 2008). Bioarchaeologists have found various
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grave styles throughout their excavations and have recorded four distinct types of graves. The
first style is a subsurface vault, roughly 35 cm above the floor, covered with a mudbrick mastaba
superstructure (Bowen, 2003). The second style is a rectangular pit with sloping sides, narrowing
towards the bottom and is covered with a false mud-brick floor and finished with mastaba
(Bowen, 2003). The third style is a variation of the second type and omits the false floor (Bowen,
2003). Finally, the fourth style is a simple pit with the fill above the body covered by a low earth
mound that was gypsum coated (Bowen, 2003). The individuals found in the graves were
wrapped in a linen shroud that was secured with woven linen ties wound in a crisscross manner
and placed directly into the pit in a supine position (Bowen, 2003).

Hair in Bioarchaeological Studies
The robust structural morphology and chemistry of the hair shaft are responsible for its
survival in the archaeological record, thus allowing bioarchaeologists to use it for studies. On
occasion, hair is better preserved than other tissues such as bone collagen in the archaeological
record (Wilson, 2005). This is because once the hair shaft has undergone keratinization it does
not remodel further as do other tissues such as bone or muscle. Hair is ideal for archaeological
studies because it captures information about the biological organism from their final months or
years of life depending on the length of the hair (Wilson, 2005).
The study of human hair is gaining increasing importance in archaeological studies. Hair
has shown to be useful for addressing questions relating to dietary reconstruction, investigation
of seasonality, assessment of geographic mobility, environmental toxicology, drug analysis,
DNA studies, and much more (Wilson et al., 2007). For example, hair analysis has been used in
the area of paleodietary analysis with the use of stable isotopes as chemical signatures that
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reconstruct broad categories of diet (Wilson, 2005). Archaeologists use the photosynthetic
pathways of CO2 of the plant consumed by a biological organism to understand the categories of
diet. Sulfur, carbon, and nitrogen isotopes were used to understand the adaptation of highland
migrants to a predominantly marine diet at Pisagua, N. Chile from 1000 B.C. (Wilson, 2005).
As an adaption from biomedical applications, the use of trace element analysis of
archaeological hair samples is growing to be increasingly more common (Wilson, 2005). The
first major use of trace element analysis of archaeological hair was published in 1983, where
researchers used ICP-MS on the hair of 168 recovered samples from two Christian-era Nubian
cemeteries at Kulubnarti in Sudan. The results generated from the analysis were compared
alongside paleopathological data and showed that the incidence of porotic hyperostosis was
correlated to the low levels of iron and magnesium (Wilson, 2005).
To study archaeological hair samples effectively, a firm understanding of the decay of
hair in this context is needed to evaluate the reliability of the information from the remains. Hair
used in archaeological studies may vary in their state of preservation due to decompositional
issues related to the body (Wilson, 2008). Factors such as bacterial activity, temperature, and
degree of exposure have the ability to influence the rate of tissue degradation. Although organic
compounds can rapidly decay due to the physio-chemical activity and bacterial environment, hair
fibers are among some of the biological materials that can resist the influence of time and
environmental factors in some contexts (Bertrand et al., 2014). Ideal environments for hair
survival include extremely cold or dry climates and anoxic environments, like Dakhleh Oasis
(Wilson, 2005).
The biodegradation of hair is a very complicated process that involves microorganisms,
several types of keratinolytic, and various types of insects and bacteria (Bertrand et al., 2014).
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Bertrand et al. (2014) explain the biodegradation process accordingly – intact hair fibers are
resistant to attack by most proteolytic enzymes. If there is initial damage to the hair fiber, the
keratin destruction is aided by physical or microbial activity; Streptomyces spp. bacteria
enhances this decomposition. The rate of proteolysis depends largely on moisture, temperature,
and bacterial action. At later stages of the decomposition process, the proteins in the hair will
breakdown into proteoses, peptones, polypeptides, and amino acids. Proteolysis eventually leads
to the production of phenolic substances and various gases such as hydrogen sulfide, carbon
dioxide, methane, and ammonia.

Hair Growth and Structure
Hair growth is a complex process resulting from the holocrine secretion by the hair
follicle that occurs in bursts of activity (Barth, 1986). Hair grows at the rate of roughly one
centimeter per month and is an epidermally derived structure made up of the hair shaft and the
hair follicle (Harrison & Sinclair, 2003). Newly grown roots have different properties than the
tips of the hair shaft. The oldest part of the hair shaft, the tips, have gone through tremendous
environmental factors while the hair root may be less porous due to lack of weathering.
The hair shaft has three major parts; the cuticle, the cortex, and the medulla (Harrison &
Sinclair, 2003; Figure 8). The cuticle, the outer layer, is comprised of cuticle cells enclosing the
polyhedral cortical cells, composed of 6 to 8 layers of overlapping cells. The cuticle layer has a
smooth appearance; however, it may be damaged due to weathering forces such as brushing,
heat, and/or combing (Harrison & Sinclair, 2003).
The second layer, the cortex, determines many of the mechanical properties of hair such
as its color and texture, and is the main bulk of the hair shaft (Harrison & Sinclair, 2003). It is
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comprised of spindle-shaped cortical cells filled with keratin surrounded by high sulfur proteins.
The keratin filaments are made up of amino acids that form hard keratin polypeptides that form
protofilaments (Jones, 2001). Keratin chains form disulfide bonds which create a strong crosslink
between additional keratin chains. These disulfide bonds create the shape, stability, structure, and
texture of hair in the cortex. Melanocytes found in the matrix area of the follicle determines hair
color, and this is found at the base of the cortex above the follicular papilla. The third layer, the
medulla, is central in the hair shaft and is comprised of specialized cells with air space.
According to Harrison and Sinclair (2003), the medulla may be continuous along the hair shaft or
it may be absent. Although researchers have identified the medulla, many scholars argue that the
true function of the medulla is unknown.

Figure 8: A cross-section diagram of the shaft of a single strand of hair (Modified from Jones,
2001).
There are three stages of human hair growth (Figure 9) – anagen, catagen, and telogen
(Robbins & Robbins, 2012). The growing stage, also known as the anagen state, involves intense
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metabolic activity in the hair bulb. This stage last roughly for 2-6 years and has the ability to
produce hairs that can group up to 100 cm in length. The second stage is the catagen stage
(Robbins & Robbins, 2012). This also called the transition stage and lasts for only a few weeks.
During this period, the base of the bulb migrates towards the epidermal surface due to the
decrease in metabolic activity. Growth factors such as EGF1 and FGF5 and neurotrophins p53,
BDNF, BMPRIa, and TGFβ1 promote the transition from anagen to catagen. The final stage,
also called the telogen stage, is considered the "resting period." This stage lasts for only a short
time, roughly 4-8 weeks, and is characterized by the termination of growth and the base of the
bulb has atrophied to the point at which it approaches the level of the sebaceous canal (Robbins
& Robbins, 2012).

Figure 9: Illustration demonstrating the three stages of growth for human hair fibers (Modified
from Robbins, 2012).

New hair begins to grow beneath the telogen follicle, pushing the old telogen fiber out at
the beginning of a new growth cycle (Robbins & Robbins, 2012). The hair cells at the dermal
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papilla move upward, while the melanocytes produce hair pigment that is interwoven into each
growing hair fiber through the cortical and medullar cells. Chemical messengers and androgens
control the maturation process of human head hair over an individual's lifetime. As an individual
ages, their hair composition changes throughout time (Robbins & Robbins, 2012).

Bioarchaeology of Care
In a community, the perception of what is considered "health" and "disease" and the care
they require is shaped by various factors such as values, cultural norms, belief systems,
collective skills, traditions, experiences, social organization, access to resources, and
environmental factors (Tilley, 2015). For this study, we’re defining health as “a dynamic state of
wellbeing characterized by a physical, mental, and social potential, which satisfies the demands
of a life commensurate with age, culture, and personal responsibility” (Bircher, 2005:336).
The identification of care practices within the archaeological record may allow
archaeologists to extrapolate various aspects about the daily life within that society. Additionally,
identifying care in the past may allow researchers to understand healthcare practices in modern
societies. Health care provisions inferred from the archaeological record may indicate that there
was some level of disability that affected their functioning capability. This would imply that care
provisions were provided by someone in their life, whether it be family, friends, or medical
professionals, i.e. care recipients and care givers. The bioarchaeology of care theory
contextualizes human behavior as it relates to care giving and care receiving practices, allowing
for an applied and conceptual framework for analyzing the archaeological record (Tilley, 2015).
Although the bioarchaeology of care framework has the potential to provide valuable
insights into the lives of those from the past, some researchers have pointed out potential issues
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with the framework (Tilley, 2015). Various aspects of illness, such as disability and disease, are
viewed differently depending on the cultural conditions. These can only be understood when
viewed through the lens of the social, cultural, and economic conditions of the time.
Furthermore, disability is a phenomenon that is uniquely experienced by each person. Objections
to the bioarchaeology of care framework include the belief that analysis of such complex
behaviors will result in the researcher ascribing Western ontological perspectives and values to
the actors of the past (Tilley, 2015).
A plethora of literature has documented various paleopathological conditions from
human remains, which has spurred bioarchaeologists to understand how these individuals
survived potentially disabling pathological conditions (Tilley, 2015). However, researchers are
hesitant to apply post-processualist theories, that rely on interpretation, such as the
bioarchaeology of care to their analysis because archaeologists can never be definitive when
contextualizing human behavior and practices in the past. Medical interventions such as surgery,
dentistry, and pharmaceuticals are important elements in healthcare and offer information about
the medical knowledge of the time, but also about the socio-cultural environment in which
disease and health are culturally defined (Tilley, 2015).
Certain features of the disease experience will always be culturally constructed and may
be understood through the analysis of contemporaneous written records. These culturally
constructed features include an explanation of etiology, the status and social treatment of the
individual with the disease, the design and delivery of health-related care, expectations of
recovery, community and personal acceptance of disability, and social reintegration within the
community (Tilley, 2015). At the core of this framework is the effort to understand the
purposeful, conscious, and goal-directed behavior regarding health-related care in the past. In the
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past, just like today, an attempt at caregiving relies on analysis, observation, and decisionmaking brought about by a disease which is culturally defined in its severity to which it requires
care (Tilley, 2015).
The bioarchaeology of care approach attempts to contextualize past lives through the
interpretation of health-related care, medical practices, and medicine through the concepts of
agency and embodiment, both group and individual (Tilley, 2015). The collective agency of
those who take on the task of caregiving is embodied within the individual receiving the care. In
this context, human remains can be thought of as both actor and artifact. It is understood that the
care receivers are active agents in shaping the outcome of their medical treatment in conjunction
with their care givers. They are individual people who are involved with negotiating care
activities that allow them to hold their agency rather than becoming "objects".
The bioarchaeology of care framework will be applied to the data in this thesis to
examine the relationship of caregiving for the elderly potentially afflicted with Alzheimer's
disease. This study will explore the perceptions of old age and disability within the context of
caregiving in Dakhleh Oasis. According to Gowland (2017), the deterioration brought about by
old age involves a constant renegotiation of one's self and a growing reliance of social
connections to reduce the risk of increasing frailty from becoming disabled. Physical and
cognitive impairment is a normal requirement of old age; one is not disabled, just elderly. This
perception has led to the elderly being invisible in disability literature due to its focus on the
experiences of middle and young-aged disabled individuals. It has been argued that the elderly
body has been subjected to "othering" in biomedical models in which old age and disease may be
regarded as synonymous (Gowland, 2017).
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The age of disease and/or disability onset plays quite a significant role not only for the
individual experiencing the disability, but also for the carer/sufferer dynamics (Gowland, 2017)
because disability can cause a shift in power within relationships and causes the development of
new interactions and roles that are centered around dependency. This theoretical framework is
geared towards understanding the performativity surrounding the care provisions that both
positively and negatively impact the individuals and/or groups involved in disability care. The
elderly are more likely to be in a position of social and physiological dependency, requiring care
from family, friends, or neighbors. As stated previously, the examination of the elderly within
medical contexts, both past and present, has been very minimal due to the inherent assumption
that extended families and supportive communities rallied around their elderly in their old age. It
is assumed that the elderly in past contexts were respected throughout their community and were
given proper care; however, it is argued that this is unlikely because western universals cannot be
placed on all cultures throughout time and space (Gowland, 2017).

Index of Care
The bioarchaeology of care framework was designed to describe particular
methodologies for identifying and understanding evidence for health-related care (Tilley, 2012).
Health, disability, and disease are constituted as different things in different cultures. The
bioarchaeology of care framework is only able to hypothesize disability within the cultural
frameworks of a given society through the physical evidence of significant impairment. With this
in mind, assumption of care and disability is a slippery slope in which the researcher must
always be cautious not to make grandiose statements. To ensure that sweeping generalizations do
not occur, Tilley (2012) created the Index of Care for reference when using the bioarchaeology
of care framework. According to Tilley 2012, the Index of Care is comprised of four stages of
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analysis created to ensure adequate conclusions and observations that are built upon previous
stages.
The first step of the Index of Care outlined by Tilley (2012) is to determine, diagnose,
and document (Figure 11). This step records every aspect of the remains, the details of their
lifeways, and their recovery context. The researcher can move on to the next stage if there is
substantial evidence of the individual living with a serious pathological condition. Stage two of
the Index of Care is centered around inferring disability within the clinical and functional
implications of the pathological condition. To assist with the inference of disability, modern
clinical research can be used to assess realistic clinical impacts on the individual. Additionally,
Tilley (2012) states that this step is also dedicated to understanding how the pathological
condition has affected the individual’s ability to carry out everyday tasks and demands within
their environment, and if assistance would be needed on a daily basis.
The third step of the Index of Care is dedicated to understanding the components of care
within the framework of an individual’s specific pathological condition (Tilley, 2012). The
purpose of stage three is to develop a possible model of care for the afflicted individual within
the clinical and social parameters of the time period. Additionally, this stage also estimates how
many people may have assisted with care giving for this individual; was the model of care
carried out by a group of people or an individual? Lastly, stage four of the Index of Care
attempts to dive deeper into the previous three stages by exploring what the elements for the
model of care suggest about the social elements, practice, and relations of the time within that
specific context (Tilley, 2012). How do individual and group identity play within this model of
care? What agency does the caregiver and care recipient have in respect to their own roles and
this specific pathology?
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Through the Index of Care within the bioarchaeology of care framework, it is possible to
posit what care and disability may have looked like in the past (Tilley & Cameron, 2014). In
addition to helping researchers understand what care entailed, it also allows us to understand
various social relations and practices centered around disability. However, the Index of Care
methodology is not designed to produce precise answers to questions centered around disability
and healthcare in the past. Rather, the Index allows bioarchaeologists to more easily identify
instances of caregiving within the past without drawing firm conclusions (Tilley & Cameron,
2014).

Step 1: Determine, Diagnose, Document
Describe remains and explain evidence for assumed pathological condition. Document evidence for
social and mortuary context.

Step 2: Determine Disability
Identify the clinical characteristics and implications of disease. Identify whether impact on function
required care from others.

Step 3: Construct a Model of Care
Identify the different characteristics of care that may be required in response to the clinical impacts of
the disease (i.e., basic elements of care, length of care, cost of care, resources required, etc.)

Step 4: Interpretation
What are the implications of collective and individual agency in the care model created by step 3?
What were the social implications, how did individual and group identity change?

Figure 10: Content and structure of the Bioarchaeological Index of Care as outlined by Tilley
(2012) and Tilley & Cameron (2014)
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CHAPTER THREE:
MATERIALS AND METHODS
The analysis of trace element content in human hair was conducted on 26 hair samples
from two different sample groups. The first sample group consists of 13 archaeological samples
from the Kellis 2 cemetery in Dakhleh Oasis, Egypt; the second sample group consists of 13
cadaver samples (comparative sample) from the UCF College of Medicine’s Willed-Body
Program. The age, cause of death, and sex for the individuals within the cadaver sample were not
released until all data was interpreted. All 26 of the samples were prepared and analyzed by the
author in the Laboratory for Bioarchaeological Sciences, and the National Center for Forensic
Science at the University of Central Florida.

Archaeological Sample
The archaeological samples from the Kellis 2 cemetery, Dakhleh Oasis, Egypt were
obtained for this study courtesy of Dr. Lana Williams, and Dr. Tosha Dupras, and the Dakhleh
Oasis Project (DOP). The archaeological sample consists of hair from 11 adult male and female
individuals aged between 20-70 years of age, and two subadult individuals of 6 months old and 3
years old. These samples were collected from the Kellis 2 cemetery by the DOP Bioarchaeology
Team. The individuals in this sample were aged and sexed by the DOP Bioarchaeology Team
using standard aging and morphological assessment of the skeletal remains as described in
Buikstra and Ubelaker (1994). The archaeological hair samples were stored in individual, Ampac
500 SealPAK plastic bags that were labeled with a sample identifier that corresponds to their
sample group number, which can be seen in Table 3. Juveniles were used in this study identify a
possible trace element profile base line for the individuals at Dakhleh. Additionally, the juveniles
were used to detect any fallacy within the identified trace element profile of high Al, Cu, and Fe
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with low Mn, Se, and Zn. If one of the juveniles had a trace element profile that fit the profile of
someone with Alzheimer’s disease, then it is clearly fallible.
Table 3: Archaeological sample numbers with their corresponding pre- and post-wash sample
mass and overall solution mass
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1

Pre-Wash Post-Wash
Sample
Sample
Mass (mg) Mass (mg)
N/A
1.10
4.07
4.00
2.92
2.92
N/A
6.0
3.50
3.40
3.50
3.40
2.80
2.40
N/A
3.20
N/A
3.60
N/A
5.20
1.40
1.20
2.21
2.00
4.47
4.45
N/A
2.70

Vessel
Mass –
Empty (g)
5.7865
5.4953
5.5453
5.4876
5.4956
5.5088
6.5226
5.5139
5.5108
5.4686
6.4478
6.5427
5.5339
5.5651

Vessel
Mass –
Full (g)
18.3059
18.3377
17.9710
18.1697
12.2876
18.3255
19.1199
18.3413
18.1692
18.3834
19.1246
19.0468
18.9130
18.2092

Solution
Mass (g)
12.5194
12.8424
12.4275
12.6821
12.7920
12.8167
12.5973
12.8274
12.6584
12.9148
12.6768
12.5041
13.3791
12.6441

Table 4: Individual information of the samples from Kellis 2, Dakhleh Oasis, Egypt with
corresponding sample numbers and demographic estimates. Skeletal information provided by Dr.
Lana Williams
Kellis
Sample #
K089-2

Estimated
Sex
M

K091-3

F

K177-1

F

K261-2

F

K275-2

F

Estimated Kellis Individual Information
Age
61
Considerable OA; ankylosing of sacroiliacs & T6-L4
vertebrae; lytic lesion in right orbit (trachoma?);
healed fracture of right 2nd rib; bilateral
chondromalacia of patellae; 10 teeth lost antemortem
55
Very osteoporotic; 11 mandibular teeth lost
antemortem; small osteomas on frontal; spina bifida
occulta of S1-S3; bilateral chondromalacia in patellae
55
Osteoporosis of lower thoracic & lumbar vertebrae; 14
teeth lost antemortem
From previous TE study: Endocrine and/or organ
dysfunction (e.g., estrogen, brain/live/kidney)
70
Osteoporosis; healed fracture of femoral neck & T12L 1 vertebrae; advanced degenerative changes in
spine; 22 teeth lost antemortem
55
No indications visible
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A+B
K2-278

N/A

3 yr

K280-1

F

60

K281-1

M

60

K306-4

F

65

K2-398
K2-403
K407-4
K528-1

F
F
N/A
F

48
20
6 mo
55

DEH - Plane defects on deciduous maxillary canines right canine has single oblong pit & left side has 3
clustered pits; no other lesions visible
Osteoporosis; well-healed bilateral ulnar fractures;
osteolytic lesions on cranial vault & C1-T2 vertebrae;
tuberculosis; 22 teeth lost antemortem
From previous TE study: Endocrine and/or organ
dysfunction (e.g., estrogen, brain/live/kidney),
Immune response dysfunction (e.g. cancer,
tuberculosis)
Slight osteoporosis; periosteal reaction on lower limb
bones & radii; well-healed fractures of C6, T1 & L4
vertebrae; healed nasal fracture; 21 teeth lost
antemortem
Slight osteoporosis; degenerative changes in knees;
Smorl's nodes on T4, T7-T8; T12 vertebral centrum
resorbed (septicemia/tuberculosis?) 21 teeth lost
antemortem
From previous TE study: Endocrine dysfunction (e.g.,
estrogen), Immune response dysfunction (e.g. cancer,
tuberculosis)
No indications visible
No indications visible
No indications visible
Severe osteoporosis; degenerative changes in knees;
healed fracture of clavicle
Cadaver Sample

The modern cadaver samples from the UCF College of Medicine’s Willed-Body Program
were obtained for this study courtesy of the program and its director, Daniel B. Topping. The
cadaver sample group consists of 13 individuals with confirmed or suspected Alzheimer’s
disease. Individual profiles of the cadaver sample were collected from medical or legal records
obtained by the UCF College of Medicine’s Willed-Body Program. The sample consists of 11
female aged 64-101 years, and two males aged 60-80 years. The cadaver hair samples were
stored in individual plastic bags that were labeled with a sample identifier supplied by the UCF
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Willed-Body Program summarized in Table 5. Demographics for each cadaver sample have been
recorded in Table 6, showing age, sex, and known ailments.
Table 5: Cadaver sample numbers with their corresponding pre- and post-wash sample mass
and overall solution mass
Cadaver
Sample #

Pre-Wash
Sample
Mass (mg)
1.80
2.96
2.40
1.50
3.25
2.07
2.20
2.33
1.70
2.80
2.41
2.56
2.66

CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540

Post-Wash
Sample
Mass (mg)
1.70
2.80
1.80
1.50
2.90
1.10
1.60
1.80
1.30
2.60
1.80
2.10
2.60

Vessel Mass
– Empty (g)
5.5738
6.4832
6.4448
5.5494
6.4621
6.5439
6.4927
6.5256
6.5432
5.5302
6.4853
5.5487
6.5356

Vessel Mass –
Full (g)
18.2872
18.9675
18.638
18.452
19.1005
18.5724
19.0317
18.9565
18.7467
19.3149
19.074
17.6509
19.0714

Solution Mass
(g)
12.7134
12.4843
12.1932
12.9026
12.6384
12.0285
12.5390
12.4309
12.2035
13.7847
12.5887
12.1022
12.5358

Table 6: Individual information of the samples from the Willed Bodied Program at UCF with
corresponding sample numbers and known demographics
Cadaver
Sample #
CO-383

Sex

Age

Cadaver Individual Information

F

87

CO-389
CO-393

F
M

83
80

CO-394
CO-395
CO-398

F
F
F

101
84
79

CO-399
CO-400
CO-403

F
F
F

94
90
97

CO-417

M

60

CO-422
CO-528

F
F

64
64

Cardiopulmonary arrest, Multisystem organ failure, Failure
to thrive, End stage Alzheimer's disease (treated)
Atherosclerotic cerebrovascular stroke/COPD
Aspiration pneumonia, Multisystem organ failure, Dementia
w/ depression
Diseases related to advanced age
Alzheimer’s disease/dementia (treated)
Respiratory failure, Aspiration pneumonia, Myocardial
infarction
Blunt head trauma
Thoracic aortic aneurysm, Peripheral vascular disease
Cardiomyopathy/Hypertension, Congestive heart failure,
Coronary artery disease, DM II, Dementia, Depression
Right middle cerebral artery stroke, COPD, Malignant
cerebral edema, Peripheral vascular disease
Alzheimer's disease/ Dementia, Hypothyroidism
Amyotrophic lateral sclerosis
49

CO-540

F

76

Severe depression with suicidal ideation, Enterobacter
infection of upper extremities
Sample Preparation

Before washing, the samples were weighed on a microbalance and the mass was
recorded. For this study, the pre-washed sample mass was intended to be above 2.0 mg. Each
strand of hair measured roughly 2 cm each, with roughly 5-6 strands per individual. Once the
mass was recorded for each sample, the hair samples were washed three times in the
ultrasonicator for 10 minutes each cycle with 10 mL of ultrapure H 2O. The samples were then
soaked in a methanol:chloroform (2:1) solution for three hours then dried in an oven at 70
degrees Celsius for 24 hours. Once the samples finished drying in the oven, they were weighed
and the post-wash sample mass was recorded. The post-wash mass was intended to be within the
range of 1.50-3.0 mg.
The hair samples were placed in a Teflon digestion vessel with 2 mL of nitric acid of
10% concentration. The Teflon digestion vessels were placed in a microwave for 45 seconds and
reached a temperature of 70 degrees Celsius then left for 15 minutes to rest. Once the sample was
cooled indium was added as an internal standard at 0.5 uL, then the solution was diluted with
ultrapure H2O until the solution amount reached 12 mL. The samples were then analyzed in an
ICP-MS.

Statistical Analysis
Data from this study were analyzed using SPSS (Statistical Product and Service
Solutions) for Windows. The data was tested using the Shapiro-Wilks test for their distribution.
The data that was normally distributed were further analyzed using an independent t-test and the
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data were expressed as mean ± SD. A P-value of less than 0.05 was regarded as statistically
significant.

Differential Diagnosis
In order to correctly estimate the possible neurological diseases at the Kellis 2 cemetery,
it’s important to conduct a differential diagnosis. A differential diagnosis is used to generate a
list of suspected diseases that may be conflated with one another. In reviewing the clinical
literature, we’re able to generate trace element profiles of each disease being examined in this
study, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Wilson’s
disease, Autism, Down’s syndrome, Prion disease, ALS, Epilepsy, and mood disorders (i.e.,
depression, anxiety, ADD/ADHD). The elemental profiles of each neurological disease can be
found in table 8. The preceding sections will cover general information about the 9 neurological
diseases examined in the differential diagnosis.

Parkinson’s Disease
Parkinson’s disease (PD) is the second most prevalent neurological disease following
Alzheimer’s disease. PD is believed to create increased burden, both economic and social, on
societies due to its increased international prevalence (De Lau and Breteler, 2006). Parkinson’s
disease begins to affect individuals at the mean onset age of 55, with an increased risk at the age
of 70 (Dauer and Przedborski, 2003). Researchers are unaware of the etiology of PD; however,
many hypotheses have been generated. There is a small incidence of cases, roughly 5%, where
PD was inherited through familial genetics; however, the remaining 95% of PD cases do not
show a genetic linkage. In addition to the hereditary susceptibility hypothesis, researchers also
believe that PD may develop due to environmental exposure to a dopaminergic neurotoxin that
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may be exposed to individuals via food, urbanization, and many other mediums (Dauer and
Przedborski, 2003). However, the environmental hypothesis has recently become less popular
than it once was during the 20th century, which has left researchers wondering if the hereditary
susceptibility hypothesis holds more truth than once predicted.
The pathogenesis of Parkinson’s disease shows oxidative stress, mitochondrial
dysfunction, and unusual protein activity (De Lau and Breteler, 2006). According to Dauer and
Przedborski (2003), the most noteworthy hallmarks of PD include the loss of nigrostriatal
dopaminergic neurons and the increased prevalence of “lewy bodies,” which are accumulations
of a protein called alpha-synuclein in the brain. Unique to PD, the main area of pathogenesis and
cell loss is located within the SNpc, the substantia nigra pars compacta and is located within the
midbrain region. In addition, PD is also known to affect the noradrenergic, cholinergic, and
serotonergic systems, the cerebral cortex, autonomic nervous system, and the olfactory bulb. Due
to the pathogenesis within the brain, symptoms of PD include what has been termed as
“parkinsonism” which is identified as a tremor at rest, rigidity, absence of voluntary movement,
and bradykinesia (Dauer and Przedborski, 2003).
There have been many studies that examine the relationship between trace elements in
the brain and the progression of PD. Table 3 provides a brief summary of seven studies that
examined this relationship between trace elements and PD. Each of the studies used a control
group of healthy individuals and compared their seemingly “normal” levels of trace elements to a
group of individuals with confirmed PD. A prime example is reported by Gellein et al. (2008)
who conducted a study in Norway comparing 33 PD individuals to 99 individuals in a control
group and found a decrease in Cu and Zn with an increase in Fe, Se, and Mn for individuals with
PD in comparison to their control group. A decrease in Cu with an increase in the additional five
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elements being examined for this study appears to be the consistent trend within PD research
when examining trace elements within the brain.

Wilson’s Disease
Wilson’s disease was first described by American neurologist Samuel Alexander KinnerWilson in 1912 while he was working at the National Hospital at Q ueen

Square

in

London

(Lorincz, 2010). A paramount notation of Dr. Wilson’s is that the disorder was associated with
progressive lenticular degeneration of the brain accompanied by cirrhosis of the liver. Along
with his first description of Wilson’s disease in 1912, he also noted the increased copper
metabolism associated with the disease which was shown through the observation of sunflower
cataracts that develop due to the over-production of copper. In 1930, Wilson’s hypothesis
regarding copper was confirmed by the discovery of excessive copper found in the brain tissue of
deceased patients with Wilson’s disease (Lorincz, 2010).
Wilson’s disease (WD) is a rare autosomal recessive disease that presents at a low
frequency in all populations (Das & Ray, 2006). Mutations to the ATPase copper transporting
beta polypeptide (ATP7B) located on chromosome 13 is believed to be the predominant cause of
the development of Wilson’s disease. While Wilson’s disease is found worldwide, it is
particularly dominant in populations where consanguineous marriage is common. Wilson’s
disease affects roughly 1 in 30,000 people in a given population with a carrier frequency of about
1 in 90 (Das & Ray, 2006).
Before an individual is diagnosed with Wilson’s disease, they usually do not show any
symptomatic signs of disease development, however their bodies have been slowly accumulating
high amounts of copper in their brain and liver (Lorincz, 2010). The patient will not begin to
show signs of WD until around the age of 17-18. During this time the patient will begin to show
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signs of psychiatric, neurologic, and hepatic manifestations of WD. While WD can manifest in
many different ways making it difficult to create a “typical picture of WD,” researchers have
created four categories of WD symptom manifestations including dysarthric, tremor, dystonic,
and pseudosclerotic or parkinsonian (Lorincz, 2010).
While symptomatic manifestations are organized within four categories, the cognitive
impairments that accompany Wilson’s disease are dispersed into two groups – frontal lobe
syndrome or subcortical dementia (Lorincz, 2010). The manifestations of the frontal lobe
syndrome cognitive impairment include impaired social judgment, promiscuity, decreased
attention, impulsivity, apathy, and poor decision making and planning ability. Conversely, the
subcortical dementia impairment associated with WD includes memory loss, inhibition of
executive function, and slowed thinking ability. The cognitive impairment that follows the
progression of WD is due to its widespread effect on the brain. In 1912 Wilson described how
WD affects the thalamus, brainstem, subthalamic nuclei, and the frontal cortex (Lorincz, 2010).
As stated previously, Wilson’s disease is predominantly defined as a copper overload
disease of the brain. Due to the increase in copper transport and metabolism, this disturbance
causes the metabolism of other trace elements to be impaired (Skowrońska et al., 2013).
Skowrońska et al. (2013) found increased levels of copper and zinc, decreased levels of
manganese, and no change in the level of iron when compared to the control group. It is believed
that abnormal levels of manganese found in the brain are directly linked to hepatic
encephalopathy and cirrhosis of the liver. Additionally, excessive iron accumulation is linked to
increased damage to mitochondrial oxidative metabolism. Lastly, abnormal levels of zinc may
damage neurons and astrocytes in the brain (Skowrońska et al., 2013).
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Autism
Autism is a pathology with multiple influential factors observed within children with
modified levels of essential and toxic elements (Priya & Geetha, 2011). Autism Spectrum
Disorder (ASD) is defined predominantly through behavioral alterations such as impaired social
communication, interaction, and repetitive mannerisms with a median onset of 36 months
(Blaurock-Busch et al., 2012). ASD is predominantly defined and characterized by behavioral
traits due to the fact that researchers have been unable to pinpoint the biological etiology of this
disorder. Although the etiology of ASD is not known, it is hypothesized that an excess or lack of
trace elements may play a role in its development and severity. Various studies have examined
the levels of trace elements in the brains of individuals with ASD to discern how trace elements
such as Cu, Se, Zn, Fe, Mn, Al, play a role in the disease.
Research has shown that altered levels of copper in the brains of individuals with ASD
directly affects the function of gamma aminobutyric acid (GABA) (Priya & Geetha, 2011).
GABA is predominantly known for its conversion from glutamate to γ-aminobutyric acid,
however, the altered levels of copper affect the glutamate conversion into γ-aminobutyric acid.
Research has shown that excessive glutamate has the potential damage and kill neurons (Tinkov
et al., 2019). Tinkov et al. (2019) show that there is an almost unilateral decrease in elemental
levels, aside from aluminum and manganese which increased in patients with ASD. Within this
study, the only element that was shown to be of any statistical significance was selenium which
produced a p value less than 0.05 as shown in Table 4.
Conversely, Blaurock-Busch et al. (2012) found that the decrease of Al in individuals
with ASD may interact metabolically with nutritionally essential elements and that Fe deficiency
increases absorption of cadmium, lead, and aluminum. Blaurock-Busch et al. (2012) also found
deficient levels of calcium, iron, manganese, zinc, and selenium for individuals with ASD.
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Down’s Syndrome
Down’s syndron (DS) is a very prevalent, genetically complex, disorders associated with
trisomy 21 (Grabeklis et al., 2019). A trisomy is a chromosomal condition characterized by an
additional chromosome. The initial diagnosis of DS was in 1959 due to physicians discovering
the presence of an extra 21st chromosome (Sherman et al., 2007). Researchers believe that 95%
of individuals with DS have this chromosomal abnormality due to issues during gamete
formation that cause the abnormal segregation of chromosomes. Beyond the 95%, roughly 1% of
individuals develop DS due to somatic mosaicism, with 4% developing DS as a result of
chromosome 21 translocations (Sherman et al., 2007). There are many issues that may develop
as a result of DS, such as cardiovascular issues, immune deficiency, and neurodegenerative
diseases that have the possibility of affecting life expectancy (Grabeklis et al., 2019).
Additionally, individuals with DS may also develop issues with various metabolic disorders
including thyroid issues, celiac disease, and obesity (Kadrabová et al., 1996).
The extra 21st chromosome found within individuals with DS causes many issues with
the processing of the amyloid precursor protein (APP), thus resulting in many individuals with
DS to develop Alzheimer’s disease later in life (Menéndez, 2005). While individuals with DS
display a wide array of health issues that develop with their DS, the development of Alzheimer’s
disease later in life appears to be the singular homogenous feature amongst the majority of cases.
This is because the addition of a 21st chromosome leads to an increase in the APP gene in the
brain, thus causing an overproduction of senile plaques (Menéndez, 2005).
Grabeklis and colleagues conducted a study in 2019 where they assessed the level of
trace elements and minerals within 40 individuals with Down’s syndrome and 40 control
individuals. The authors found that almost all of the elements analyzed were found to be
decreased in individuals with Down’s syndrome when compared to the control group, aside from
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iron that was found to increase. Grabeklis et al. (2019) found that the hair levels of these trace
elements exceeded the respective control values by as much as 54%. As summarized in Table 5,
the three elements that were found to be statistically significant were copper, zinc, and iron;
however, the p-value for iron was not given. This study conducted by Grabeklis et al. (2019) is a
perfect example of what we expect to see from hair analysis of individuals with Down’s
syndrome. It is predicted that there will be a decrease in Cu, Al, Zn, Se, and Mn, with an increase
in Fe.

Huntington’s Disease
Huntington’s disease (HD) is an autosomal dominant disorder of the brain that, in
addition to cognitive decline and behavioral issues, deteriorates the physical mind (Walker,
2007). Huntington’s disease is known to cause chorea which is a movement disorder that causes
irregular and sporadic movements of the body. In addition to chorea, individuals with HD are
known to develop a secondary movement disorder called dystonia in which a person’s muscles
will experience uncontrollable contraction (Walker, 2007). Huntington’s disease is relatively rare
within the modern world with a prevalence of roughly 5-10 individuals per 100,000 (Roos,
2010). Huntington’s disease is known to predominantly affect individuals of European descent
with an onset age of roughly 30-50 years (Roos, 2010).
Huntington’s disease develops due to a mutant protein coined “huntingtin” which is a
byproduct from “an expanded CSG repeat leading to a polyglutamine strand of variable length at
the N-terminus” (Walker, 2007:121). Researchers have reported that huntingtin is present within
all mammalian and human cells, with the brain being the area with the highest concentration.
Neurological alterations during the pathogenesis of Huntington’s disease involve major cell loss
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and brain atrophy in the putamen and the caudate. According to Walker (2007:125), additional
brain regions affected by HD include the “substantia nigra, cortical layers 3, 5, and 6, the CA1
region of the hippocampus, the angular gyrus in the parietal lobe, purkinje cells of the
cerebellum, lateral tuber al nuclei of the hypothalamys, and the centromedial-parafascicular
complex of the thalamus.”
Researchers have noted that individuals with HD show a decreased amount of
neurofilaments, nerve fibers, microtubule-associated protein 2 and tublins (Walker, 2007). This
information is worth noting due to their involvement in synaptic function, axonal transport, and
cytoskeletal integrity within the brain. These physiological alterations suggest critical
information regarding the pathogenesis of HD and its alteration of the human brain (Walker,
2007).
There are not many studies regarding the analysis of trace elements in individuals with
HD, however, a study conducted by Squadrone et al. (2020) enrolled 36 individuals to
understand the correlation between trace elements and HD. This study used two sample groups
with 18 individuals diagnosed with HD and 18 individuals that were labeled as the “healthy
control.” Squadrone and colleagues found that there were high levels of iron, zinc, and selenium
for individuals with HD in comparison to the healthy control group. However, levels of copper
and manganese were found to decrease in individuals with HD when compared to the control
group (Squadrone et al., 2020).

Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder that is
characterized by the decline of motor neurons at the spinal or bulbar level (Zarei et al., 2015).
First described by Jean-Martin Charcot, a French neurologist, in 1869, ALS is considered a rare
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neurodegenerative disorder with an incident rate of roughly 1.5 per 100,000. Although ALS is
rare, the disease became well known in the US when baseball player Lou Gehrig was diagnosed
in 1939 which created an influx of awareness (Hardiman et al., 2011). ALS manifests in 2 forms,
sporadic and familial ALS. The most common form of ALS is sporadic which constitutes
roughly 90-95% of ALS cases. Familial ALS (FALS) affects the remaining 5-10% of cases that
are characterized by a dominant genetic inheritance factor (Zarei et al., 2015).
ALS begins to manifest between the ages of 50 to 65 with a median onset of 64
(Hardiman et al., 2011). It is extremely rare for individuals to develop “early on-set” ALS.
Roughly 5% of reported ALS cases have an onset of <30 years of age (Zarei et al., 2015). The
most common manifestations of ALS include twitching, muscle weakness, and cramping that
leads to eventual impairment of muscles. In very advanced cases of ALS patients will develop
dyspnea (labored breathing) and dysphagia (swallowing difficulties).
The leading cause of ALS pathogenesis is a mutation is the gene encoding the antioxidant
enzyme superoxide dismutase 1 (SOD1) (Zarei et al., 2015). Due to the structural instability of
this enzyme, the mutant SOD1 causes a misfold in the mutated enzyme which leads to the
degeneration of motor neurons within the central nervous system (Zarei et al., 2015). The exact
mechanism progressing the action of mutant SOD1 and the consequent neurodegeneration is not
fully understood at this time. However, proposed hypotheses cite functional and structural
abnormalities of mitochondria, glutamate excitotoxicity, and impaired axonal structure of
transport defects (Hardiman et al., 2011).
Many studies have been conducted to elucidate the relationship between trace elements
and the pathogenesis of ALS. Bergomi et al. (2002) conducted a study with 52 individuals, 22
with confirmed ALS and 40 healthy controls. They found that Cu, Mn, Zn, and Fe levels were
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lowered in patients with ALS, however it was so minute that it was recorded as statistically
insignificant. Additionally, Bergomi and colleagues found that Al showed little to no
involvement in individuals with ALS. This study contrasts the investigation conducted by Peters
et al. (2016) that found that Cu, Mn, and Se were positively correlated with ALS. This study was
conducted on a larger sample population of 163 ALS patients and 229 controls. However, like
Bergomi et al. (2002), Peters et al. (2016) found that Zn levels decreased with ALS patients in
comparison to the control group. Finally, Forte et al. (2017) conducted a study on 34 ALS
patients and 30 controls and found increased levels of Cu and Se with ALS patients and a
statistically insignificant increase in Zn levels.

Epilepsy
Epilepsy is a very common neurological condition that affects roughly 50-65 million
individuals worldwide (Banerjee et al., 2009). Epilepsy does not have a median onset of age
since it’s known to affect individuals of all ages (Duncan et al., 2006). Epilepsy is defined as a
neurological condition consisting of recurrent epileptic seizures caused by an unprovoked
neurological response. Researchers believe that the high incidences of cases across the globe can
be explained by factors such as limited access to healthcare, low socioeconomic status, and
environmental factors like neurocysticercosis (Banerjee et al., 2009).
Epilepsy can be divided into two categories of seizure types classified by the
International League Against Epilepsy (ILAE) (Duncan et al., 2006). These categories are partial
seizures and generalized seizures. Partial (focal) seizures are characterized by the stimulation of
the brain within one focal area that triggers a seizure event. Conversely, generalized seizures are
characterized by the stimulation of the entire brain that triggers a seizure event (Banerjee et al.,
2009). According to Moshé et al. (2015) epileptic seizures are caused by abnormal
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synchronization of neurons that create a disruption of communication within the brain, thus
causing aberrant electrical discharges. Thom and colleagues (2008) explain that individuals with
epilepsy are thought to have developed the conditions as a clinical manifestation of other
neurodegenerative diseases such as Alzheimer’s disease or MS. While researchers are unsure of
the underlying mechanism that connects epilepsy to other neurodegenerative diseases, the
toxicity of amyloid-β on synaptic transmission is warranting further consideration (Thom et al.,
2008).
The trace element studies that have been conducted on patients with epilepsy are
predominantly focused on how certain elements can be used as a treatment for this condition.
Ilhan et al. (2004) conducted a study with 31 epileptic patients and 19 healthy controls to
determine how essential trace elements are being affected by epilepsy within the body. They
found that epileptic individuals had higher levels of Cu and Mn, followed by a decrease in Zn;
however, the decrease in Zn was not statistically significant. Saad and colleagues (2014)
conducted a study with 40 epileptic individuals and 40 healthy controls and found that Zn
significantly decreased in patients with epilepsy. Additionally, both Cu and Se decreased,
however the decrease in Cu was not statistically significant while the decrease in Se was
significant. Lastly, Saghazadeh et al. (2015) reviewed literature from past epilepsy studies that
examined trace element levels and found that the majority of researchers reported a decrease in
Zn, while Cu and Se levels were found to not have any statistically significant changes.

Prion Disease
Prion disease is a category of neurodegenerative diseases whose pathogenesis begins with
the mutation of the prion protein (PrPSc) (Mead, 2006). Within the category of prion disease,
there are four specific diseases that involve the prion protein and they are Gerstmann-Straussler61

Scheinker syndrome (GSS), Creutzfeldt-Jakob disease (CJD), Kuru, and fatal familial insomnia
(FFI) (Safar et al., 2005). To break down the category of prion disease even further, the diseases
can be typecast into sporadic, inherited, or acquired etiologies.
According to Safar and colleagues (2005), sporadic accounts of prion disease classify
roughly 85% of all cases, inherited prion disease cases affect roughly 10-15%, while acquired
prion disease affects less than 1% of reported cases world-wide. Prion disease is extremely rare,
with an incidence rate of only 1-2 people per million across the globe (Collinge, 2005). Although
prion disease is extremely rare, there has been an uptick in studies regarding the etiology and
pathogenesis of these diseases due to increasing worry that the epizootic of bovine spongiform
encephalopathy (BSE) could possibly threaten public health via infected animal tissue (Collinge,
2005).
Thackray and colleagues (2002) examined the role of trace elements in prion disease on
10 mice and found a general trend of high Mn levels with decreased Zn and Cu. Hesketh and
colleagues (2008) corroborated these findings through their study examining 17 individuals with
prion disease. They found that there was a very high increase in Mn in individuals with prion
disease, which led researchers to believe that Mn has the ability to bind onto the PrPSc protein
and alter it. Additionally, they found a general decrease in Cu and an increase in Fe levels.

Mood Disorders (Anxiety, Depression, Bipolar Disorder, ADHD/ADD)
Mood disorders affect millions of people worldwide and have always been at the
forefront of public health concerns due to their increased prevalence (Piao et al., 2017). While
mood disorders such as anxiety, depression, bipolar disorder, and ADHD/ADD have different
etiologies, they can all be boiled down to three interacting categories: genetics, environment, and
intrapersonality (Piao et al., 2017). Additionally, mood disorders can manifest differently from
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one person to the next via chronic, transient, or recurrent symptoms. Although these mood
disorders vary in their manifestation, it is noted that one of the significant root causes for the
pathogenesis is zinc deficiency (Mlyniec et al., 2017).
Mlyniec and colleagues (2017) found that individuals with anxiety and depression have
significantly decreased levels of Zn. Additionally, a Zn-deficient diet was found to be directly
correlated with anxiogenic-like behavior. Mlyniec et al. (2017) explain that Zn was directly
related to Cu, where low levels of Zn were correlated with an increase in Cu levels. This
information is consistent with the trace element profiles of individuals with anxiety and
depression as outlined by Mlyniec et al. (2017). Lastly, the researchers found that anxious and
depressed individuals had very high levels of Mn, and almost mimicked levels seen in
Parkinson’s patients that experience tremors due to the high levels of Mn in their systems.
However, this study directly contradicts that of Dean et al. (2019) who reported low levels of
Mn, along with Cu, Zn, and Se in patients with major depressive disorder that committed suicide.
Yang et al. (2019) conducted a study to understand the trace element profile of
individuals with attention deficit hyper disorder (ADHD) and attention deficit disorder (ADD).
They studied 419 individuals with ADHD/ADD and 395 individuals as a healthy control group.
Yang et al. (2019) found that individuals with ADHD/ADD had much lower Zn levels in
comparison to the healthy control group. Additionally, Fe, Cu, and Se levels showed unchanging
consistency between the two groups. Mustak et al. (2010) analyzed biological samples of 117
individuals with bipolar disorder and 25 healthy controls to understand the difference in trace
elements between the two. They found patients with bipolar disorder 1 and 2 had increased Cu,
Al, and Mn levels. Additionally, Cu and Al levels were increased while Fe and Zn levels
decreased in bipolar 2 depression patients and bipolar V patients.
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Summary of Differential Diagnosis
In order to understand the full spectrum of health and disease within the Kellis 2
cemetery, it is important to create trace element profiles of the 10 neurological disorders being
examined within this study. Table 7 summarizes the element profiles for the 10 neurological
disorders previously mentioned in this chapter. This table was created with the “normal” trace
element profile created by Miekeley et al. (1998) as a baseline. Although neurological disorders
do not present unilaterally amongst individuals within a given population, this chart is a good
baseline for interpretation of data and understanding co-morbidities within the Kellis 2
population.

Table 7: Summary of the elemental profiles of the 10 neurological disorders examined for the
differential diagnosis of this study
Alzheimer’s
disease

Aluminum
Increase
(>12 μg/g)

Copper
Increase (> 35
μg/g)

Iron
Increase
(>15 μg/g)

Manganese
Decrease
(<0.26 μg/g)

Selenium
Decrease
(<0.38
μg/g)

Zinc
Decrease
(< 125
μg/g)

Parkinson’s
Disease

Increase (>
12 μg/g)

Decrease (< 13
μg/g)

Increase
(>15 μg/g)

Increase
(>0.75 μg/g)

Increase
(>0.70
μg/g)

Increase
(>165
μg/g)

Wilson’s
Disease

No Change;
Normal
Levels; No
Scientific
Reporting

Increase (> 35
μg/g)

Decrease
(<0.26 μg/g)

Decrease
(<12 μg/g)

Decrease (< 13
μg/g)

No
Change;
Normal
Levels;
No
Scientific
Reporting
Decrease
(<0.38
μg/g)

Increase
(>165
μg/g)

Autism

No
Change;
Normal
Levels;
No
Scientific
Reporting
Decrease
(< 6 μg/g)

Down’s
Syndrome

Decrease
(<12 μg/g)

Decrease (<13
μg/g)

Increase
(>15 μg/g)

Decrease
(<0.26 μg/g)

Decrease
(<0.38
μg/g)

Decrease
(<125
μg/g)

Huntington’s
Disease

No Change;
Normal
Levels; No
Scientific
Reporting

Decrease (<13
μg/g)

Increase
(>15 μg/g)

Decrease
(<0.26 μg/g)

Decrease
(<0.38
μg/g)

Decrease
(<125
μg/g)

64

Decrease
(<0.26 μg/g)

Decrease
(<125
μg/g)

Aluminum
No Change;
Normal
Levels; No
Scientific
Reporting
No Change;
Normal
Levels; No
Scientific
Reporting

Copper
No Change;
Normal
Levels; No
Scientific
Reporting
Increase (> 35
μg/g)

Prion Disease

No Change;
Normal
Levels; No
Scientific
Reporting

Decrease (< 13
μg/g)

No
Change;
Normal
Levels;
No
Scientific
Reporting
Increase
(>15 μg/g)

Mood
Disorders

Increase (>
12 μg/g)

Increase (> 35
μg/g)

Decrease
(< 6 μg/g)

Amyotrophic
Lateral
Sclerosis
(ALS)
Epilepsy

Iron
Decrease
(< 6 μg/g)

(Depression,
Bipolar Disorder,
Anxiety Disorder,
ADHD, etc.)
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Manganese
No Change;
Normal
Levels; No
Scientific
Reporting
Increase
(>0.75 μg/g)

Increase
(>0.75 μg/g)

Increase
(>0.75 μg/g)

Selenium
Decrease
(<0.38
μg/g)

Zinc
Decrease
(< 125
μg/g)

No
Change;
Normal
Levels;
No
Scientific
Reporting
No
Change;
Normal
Levels;
No
Scientific
Reporting
Decrease
(<0.38
μg/g)

Decrease
(< 125
μg/g)

Decrease
(< 125
μg/g)

Decrease
(< 125
μg/g)

CHAPTER FOUR:
RESULTS
To interpret the results, this study will examine each element independently of one
another, starting with aluminum (Al). This is done to closely identify patterns occurring within
each group of elements throughout the two samples. General trends, comparisons, and
concluding remarks between all six elements will be done at the end of this chapter and
throughout Chapter 5. Comparisons and differences between the cadaver sample and Kellis 2
sample will be made within the examination of each independent element.

Summary of Al Results and Data Trends
The normal range of Al in modern human hair is less than 12 μg/g (Miekeley et al.,
1998). Of the 28 samples examined 13 individuals were found to have Al levels equal to or
greater than 12 μg/g. The Al values for the cadaver samples and the Kellis 2 samples are
summarized in Tables 8 and 9.
For the cadaver samples, only 3 individuals (CO-383, CO-399, CO-400) presented Al
levels above 12 μg/g (Table 8); however, this could be explained by the prescription medication
many of the individuals within this sample were taking for their Alzheimer’s disease (AD) and/or
other medical complications. Medication for Alzheimer’s disease focuses on inhibiting the
uptake of certain elements, such as Cu and Al, to slow down or stop the progression of AD. An
example of this is CO-395 who had treated AD; however, their Al level is 3.18 μg/g which is
considered to be within a normal range. Conversely, CO-383 also had treated AD, but their Al
levels are outside the range of normal at 22.15 μg/g which does not support the hypothesis that
AD medication may explain the frequency of low Al levels within the cadaver sample. The high
Al value for CO-383 could be explained by the length of time she was taking medication before
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she passed. If she wasn’t taking AD medication for a very long time, it’s possible that the
medication did not have an adequate amount of time to lower her trace element values; however,
this information is not provided so this must simply be speculative.
Table 8: Recorded Aluminum (Al) levels from cadaver samples given in μg/g. Samples with Al
levels above 12 μg/g are denoted with an asterick
Cadaver
Sample #
CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540
Median #

Sex

Age

F
F
M
F
F
F
F
F
F
M
F
F
F

87
83
80
101
84
79
94
90
97
60
64
64
76

Aluminum
(Al) μg/g
22.15*
0.02
4.00
9.04
3.18
6.83
14.67*
17.00*
10.29
6.14
8.06
3.59
2.57
6.83

For the Kellis 2 samples, 10 individuals presented Al levels over 12 μg/g. The highest Al
level recorded for the Kellis 2 samples is K2-398 at 94.756 μg/g, while the lowest recorded is
K2-403 at 4.66 μg/g. Several of the Kellis 2 samples present Al levels that are astronomically
high when compared to the normal range of <12 μg/g. There are only three individuals from the
Kellis 2 sample group that have Al levels within the range of <12 μg/g, and that is K2-403, K2278, and K091-3. The Al values for the Kellis 2 samples are summarized in Table 9.
There may have been many opportunities for the people of Kellis to come into contact
with excessive amounts of Al. As stated previously in Chapter 2, Wiedeman & Bayer (1983)
found trace amounts of Al in ancient papyri, the third most abundant next to oxygen and carbon.
Additionally, aluminum phosphate was commonly found within many minerals in ancient Egypt,
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as described by El Agami et al. (2005). It is also not uncommon to find Al in water sources, both
today and in the past, and is not outside the scope of possibility when trying to understand these
Al levels for the Kellis population (Soltan, 1999). Lastly, Groff (2015) outlines that many sick
individuals would migrate to Dakhleh to take advantage of the alum minerals within the hot
springs in the area, since they were believed to heal the afflicted of their illnesses.
Table 9: Recorded Aluminum (Al) levels from Kellis samples given in μg/g. Samples with Al
levels above 12 μg/g are denoted with an asterick.
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1
Median #

Sex

Age

M
F
F
F
F
F
N/A
F
M
F
F
F
N/A
F

61
55
55
70
55
55
3 yr
60
60
65
48
20
6 mo
55

Aluminum (Al)
μg/g
14.85*
8.71
25.21*
43.44*
14.60*
27.37*
9.07
29.41*
16.32*
N/A
94.75*
4.66
13.31*
14.03*
15.59

The data for the cadaver Al samples were shown to be normally distributed. When testing
for skewness and kurtosis, normal ranges are found within -1.96 to +1.96. The cadaver Al levels
were +1.56 for skewness and +0.331 for kurtosis, showing that they are within the normally
distributed range. Additionally, the p-value for the cadaver Al levels was shown to be not
statistically significant at 0.283, with most levels at or under the normal level of 12 μg/g, which
is greater than the significance level chosen for this study at 0.05.
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Table 10: Statistics for cadaver Al levels

The data for the Kellis 2 Al levels were found too not be normally distributed. The Kellis
Al levels were +4.40 for skewness and +6.817 for kurtosis, showing that they are not within the
normally distributed range. This information can be found in Table 10. Additionally, the p-value
for the Kellis Al levels was shown to be statistically significant at 0.000, which is lower than the
significance level chosen for this study at 0.05.

69

Table 11: Statistics for Kellis 2 Al levels

Overall, the Al levels from Kellis 2 have shown to be higher overall and less normally
distributed than the cadaver sample, which is shown in table 11. While there is some overlap
between the two, the Kellis 2 samples show to have higher levels of Al when compared to the
cadaver samples. Since high Al levels are known to cause toxicity such as neurological disorders,
cardiovascular disease, and kidney disease, it is not outside the scope of possibility to assume
that the people of Kellis most likely experienced these issues.
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Figure 11: Box plot comparing the Al levels from the cadaver samples (COAl) and Kellis (K2Al).
On average, the Kellis 2 samples show much higher levels of Al than the cadaver samples. The yaxis represents trace element values in μg/g with astericks (*) representing outliers.

Summary of Cu Results and Data Trends
Normal ranges of Cu in human hair are within 13 – 35 μg/g (Miekeley et al., 1998). Ten
of the cadaver samples have Cu levels below 13 μg/g, while three samples were shown to be
within 13 – 35 μg/g, and no samples above the threshold of 35 μg/g. Conversely, ten of the Kellis
2 samples have Cu levels below 13 μg/g, while five samples were found to be within the 13 – 35
μg/g range, and no samples were found to be above the 35 μg/g threshold.
Copper (Cu) is instrumental in the pathogenesis of many neurological diseases, especially
in the six pathological conditions considered in this study as part of the differential diagnosis.
The recorded Cu levels for the cadaver sample do not support the hypothesis that high copper
levels are present in individuals with Alzheimer’s disease. The individuals in the cadaver sample
with confirmed Alzheimer’s disease (CO-383, CO-422, CO-393, CO-403, CO-395) all have Cu
levels below the 13 μg/g threshold, with the exception of CO-403 at 13.89 μg/g. As stated
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previously, this can be explained by the fact that these individuals were reported to be treating
their Alzheimer’s disease, which inhibits the uptake of many elements such as Al and Cu. The
Cu values for the cadaver samples are summarized in Table 12.
Table 12: Recorded Copper (Cu) levels from cadaver samples given in μg/g. No individuals are
found to be higher than the normal range of 13 – 35 μg/g.
Cadaver
Sample #
CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540
Median #

Sex

Age

F
F
M
F
F
F
F
F
F
M
F
F
F

87
83
80
101
84
79
94
90
97
60
64
64
76

Copper (Cu)
μg/g
4.50
0.08
10.43
5.89
6.47
14.56
9.48
13.67
13.89
12.22
8.11
5.76
3.48
8.11

Within the Kellis 2 samples, ten individuals presented Cu levels below 13 μg/g. The
highest Cu level recorded for the Kellis 2 samples is K2-398 at 25.84 μg/g, while the lowest
recorded is K261-2 at 2.14 μg/g. Overall, the Cu levels for the Kellis 2 sample are normally
distributed with none of the samples exceeding 35 μg/g. There are 5 individuals that are within
the normal Cu range of 13-35 μg/g. The Cu values for the Kellis 2 samples are summarized in
Table 13.
People in ancient Egypt used Cu quite frequently in their society. As stated in Chapter 2,
copper was mined and Cu ore was frequently used in ancient Egypt for various purposes
(Borkow & Gabbay, 2009). Copper was used to sterilize daily drinking water and wounds, and
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during the Roman occupation, utensils were made from Cu to minimize the spread of diseases
(Sipos et al., 2004). Ancient Egyptians also used copper silicate for eyeshadow since it gave off a
vibrant blue-green color (Sipos et al., 2004).
Table 13: Recorded Copper (Cu) levels from Kellis samples given in μg/g. No individuals are
found to have higher Cu levels than the normal range of 13 – 35 μg/g.
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1
Median #

Sex

Age

M
F
F
F
F
F
N/A
F
M
F
F
F
N/A
F

61
55
55
70
55
55
3 yr
60
60
65
48
20
6 mo
55

Copper (Cu)
μg/g
4.86
8.21
24.95
2.14
6.94
14.60
9.26
4.02
3.68
5.22
25.84
11.70
19.01
2.15
8.21

The Cu data for the cadaver samples was shown to be normally distributed. When testing
for skewness and kurtosis, normal ranges are found within -1.96 to +1.96. The cadaver Cu levels
were -0.261 for skewness and -0.715 for kurtosis, showing that they are within the normally
distributed range. This information can be found in table 14. Additionally, the p-value for the
cadaver Cu levels was shown to not be statistically significant at 0.699, which is greater than the
significance level chosen for this study at 0.05.
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Table 14: Statistics for cadaver Cu levels

The data for the Kellis 2 Cu levels were found to be normally distributed. The Kellis Cu
levels were 1.52 for skewness and -0.283 for kurtosis, showing that they are within the normally
distributed range. This information can be found in Table 15. Additionally, the p-value for the
Kellis Cu levels was shown to not be statistically significant at 0.058, which is greater than the
significance level chosen for this study.
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Table 15: Statistics for Kellis 2 Cu levels

Overall, the Cu levels from the two samples are normally distributed with no major
outliers, which is illustrated in Figure 13. While neither sample showed abnormal Cu levels, the
Kellis 2 samples have higher levels of Cu when compared to the cadaver samples. While
abnormally high Cu levels were not reported, low levels of Cu can indicate breast cancer, stroke,
liver cirrhosis, cardiovascular disease, and/or anemia (Wolowiec et al., 2013; Mikulewicz et al.,
2013). It is possible that the ten individuals from the Kellis 2 cemetery with Cu levels below 13
μg/g, they may have experienced some of these health issues.
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Figure 12: Box plot comparing the Cu levels from the cadaver samples (COCu) and Kellis
(K2Cu). On average, the Kellis 2 samples show much higher levels of Cu than the cadaver
samples.
Summary of Fe Results and Data Trends
Normal ranges for Iron (Fe) for humans are 6-15 μg/g (Miekeley et al., 1998). Of the 28
samples examined across the two study groups, 17 individuals were found to have Fe levels
outside the normal range. The Fe values for the cadaver samples and the Kellis 2 samples are
summarized in Tables 16 and 17.
For the cadaver samples, six individuals presented Fe levels outside of the 6-15 μg/g
range. CO-383, CO-399, and CO-400 presented Fe levels higher than 15 μg/g, while CO-540,
CO-389, and CO-395 presented Fe levels lower than 6 μg/g. CO-383 was confirmed to have
Alzheimer’s disease, so this explains their high Fe levels. However, CO-395 also had
Alzheimer’s disease, but their Fe levels are very low at 4.97 μg/g. This is interesting because
CO-395 and CO-383 were the only two with records of treated Alzheimer’s, however their Fe
levels are vastly different. This leaves the question about whether the medication they were
taking for Alzheimer’s can explain the low Fe levels in CO-395 since the medication limits
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element uptake. However, lower levels of Fe would be expected in individual CO-383, but the
difference could be explained by simple human variation or the length of their respective AD
treatments. The Fe values for the cadaver sample can be seen in Table 16.
Table 16: Recorded Iron (Fe) levels from cadaver samples given in μg/g. Individuals with Fe
levels above 6-15 μg/g are denoted with an asterick.
Cadaver
Sample #
CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540
Median #

Sex

Age

F
F
M
F
F
F
F
F
F
M
F
F
F

87
83
80
101
84
79
94
90
97
60
64
64
76

Iron
(Fe) μg/g
19.44*
0.05
6.61
13.63
4.97
9.84
24.20*
18.76*
8.20
7.75
15.82
11.13
5.54
9.84

For the Kellis 2 sample, 11 individuals presented Fe levels over 15 μg/g. The highest Fe
level recorded for the Kellis 2 sample is K089-2 at 256.89 μg/g, while the lowest recorded is
K407-4 at 8.63 μg/g. Overall the Fe levels for the Kellis 2 sample are astoundingly high when
compared to the normal range of 6-15 μg/g. There are only four individuals from Kellis 2 that are
within the normal Fe range, K2-403, K407-4, K091-3, and K528-1. The Fe values for the Kellis
2 sample can be seen in Table 17.
The people of Kellis had many opportunities to be exposed to Fe in their daily lives. As
stated previously in Chapter 2, Wainwright (1932) describes Fe as one of the most common
elements in ancient Egypt that was used for a manufacturing a multitude of objects such as
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weapons, cooking utensils, and jewlery. Additionally, Lucas (1930) explains that both men and
women in ancient Egypt used eye paints and cheek coloring such as red ochre which is
comprised of large amounts of Fe.
Table 17: Recorded Iron (Fe) levels from Kellis samples given in μg/g. Individuals with Fe levels
above 6-15 μg/g are denoted with an asterick.
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1
Median #

Sex

Age

M
F
F
F
F
F
N/A
F
M
F
F
F
N/A
F

61
55
55
70
55
55
3 yr
60
60
65
48
20
6 mo
55

Iron
(Fe) μg/g
256.89*
13.97
63.46*
59.97*
31.44*
24.42*
43.10*
47.91*
23.19*
79.41*
54.38*
11.55
8.63
15.10
43.10

The data for Fe levels in the cadaver sample was shown to be normally distributed. When
testing for skewness and kurtosis, the cadaver Fe levels were 0.641 for skewness and -0.352 for
kurtosis, indicating that they are within the normally distributed range. This information can be
found in Table 18. Additionally, the p-value for the cadaver Fe levels was shown not to be
statistically significant at 0.899, which is greater than the significance level chosen for this study
at 0.05.

78

Table 18: Statistics for Cadaver Fe levels.

The data for the Kellis 2 samples was found to not be normally distributed. The Kellis 2
Fe levels were 4.879 for skewness and 8.311 for kurtosis, showing that they are not within the
normally distributed range. This information can be found in Table 19. Additionally, the p-value
for the Kellis Fe levels was shown to be statistically significant at 0.000, which is lower than the
significance level chosen for this study at 0.05.
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Table 19: Statistics for Kellis 2 Fe levels

The Fe levels from Kellis 2 have shown to be higher overall and less normally distributed
than the cadaver sample, as illustrated in Figure 14. While there is some overlap between the
two, the Kellis 2 samples have higher levels of Fe when compared to the cadaver samples. Since
high Fe levels are known to cause toxicity that can cause neurological diseases, kidney & liver
diseases, breast cancer, periodontal disease, multiple sclerosis, osteoarthritis, and diabetes
mellitus (Wolowiec et al., 2013; Mikulewicz et al., 2013) it is not outside the realm of possiblity
to assume that the people of Kellis most likely experienced some of these issues.
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Figure 13: Box plot comparing the Fe levels from the cadaver sample (COFe) and Kellis (K2Fe).
On average, the Kellis 2 samples show much higher levels of Fe than the cadaver samples.
Summary of Zn Results and Data Trends
A normal range of Zn in humans is 125-165 μg/g (Miekeley et al., 1998). Of the 28
samples analyzed for this investigation, only two individuals were found to have Zn above 165
μg/g, while 26 individuals displayed Zn levels below 125 μg/g. The Zn values for the cadaver
samples and the Kellis 2 samples can be seen in Tables 20 and 21.
For the cadaver samples, all 13 individuals displayed Zn levels below the normal level of
125 μg/g. The low levels of Zn fit the characteristics of Alzheimer’s disease as well as other
neurological diseases considered as part of the differential diagnosis. The highest documented Zn
level within the cadaver sample is CO-400 at 41.91 μg/g, and the lowest Zn level is CO-389 at
0.179 μg/g. Although low Zn levels support the hypothesis of the presence of neurological
diseases, individuals who were recorded with not having Alzheimer’s are also displaying low Zn
levels. This can be explained by the fact that levels of Zn decrease with age, which is related to
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many ailments of old age due to Zn deprivations effect on immune function (Brown et al., 2001).
The Zn levels for the cadaver samples are listed in Table 20.
Table 20: Recorded Zn levels from Cadaver sample given in μg/g. Individuals with Zn levels
above 165 μg/g are denoted with an asterick.
Cadaver
Sample #
CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540
Median #

Sex

Age

F
F
M
F
F
F
F
F
F
M
F
F
F

87
83
80
101
84
79
94
90
97
60
64
64
76

Zinc (Zn)
μg/g
27.12
0.17
34.52
26.38
27.06
30.13
37.81
41.91
38.63
13.81
31.79
29.26
18.66
29.26

For Kellis 2, all 15 samples displayed Zn outside of the 125-165 μg/g range. Thirteen
samples showed Zn levels below 125 μg/g, while two samples showed Zn levels above 125 μg/g.
Individual K177-1 B has a Zn level of 381.69 μg/g and the Zn level for K407-4 was 567.91 μg/g.
These Zn levels are extremely high and abnormal for a healthy human being. The 13 samples
that were recorded below the 125 μg/g threshold, range from 10.76 – 44.82 μg/g, which is
extremely low for normal human function. Overall, the Zn levels from Kellis 2 appear to be
abnormally low or abnormally high. The Zn values for the Kellis 2 samples can be seen in Table
21.
Ancient Egyptians did not have many opportunities to interact with Zn in their daily
lives aside from the use of what we now know as calamine cream. This cream was used to heal
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wounds and repair skin, while simultaneously used as an anti-aging agent by women
(Frederickson et al., 2005).
Table 21: Recorded Zinc (Zn) levels from Kellis samples given in μg/g. Individuals with Zn levels
above 165 μg/g are denoted with an asterick.
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1
Median #

Sex

Age

M
F
F
F
F
F
N/A
F
M
F
F
F
N/A
F

61
55
55
70
55
55
3 yr
60
60
65
48
20
6 mo
55

Zinc (Zn)
μg/g
11.55
34.45
381.69*
15.75
24.68
10.76
24.42
15.11
21.53
11.62
44.82
24.30
567.91*
15.01
24.30

The data for the cadaver Zn samples was shown to be normally distributed. The cadaver
Zn levels showed a skewness of -1.96 and a kurtosis of 1.47, which are inside the range of -1.96
and +1.96. This information can be found in table 22. Additionally, the p-value for the cadaver
Zn levels is not statistically significant at 0.183, which is greater than the significance level
chosen for this study at 0.05.
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Table 22: Statistics of cadaver Zn levels

The data for the Kellis 2 samples is not normally distributed. The Kellis 2 Zn levels were
4.498 for skewness and 5.402 for kurtosis, showing that they are not within the normally
distributed range. This information can be found in table 23. Additionally, the p-value for the
Kellis 2 sample Zn levels was shown to be statistically significant at 0.000, which is lower than
the significance level chosen for this study at 0.05.
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Table 23: Statistics for Kellis 2 Zn levels

The Zn levels from Kellis 2 are higher overall with a greater average mean of 82.27 μg/g
when compared to the cadaver mean of 27.48 μg/g. Figure 15 illustrates the box plot comparing
the two samples, and while there is significant overlap between the two groups, Kellis 2 has
greater overall Zn values and more statistically significant outliers. Low Zn levels are known to
cause neurological diseases and anemia, while high Zn levels are known to cause cancer,
periodontal disease, ADHD, osteoarthritis, diabetes mellitus, and hepatitis C (Wolowiec et al.,
2013; Mikulewicz et al., 2013). It is very possible that the individuals from Kellis were suffering
with one, or multiple, of these ailments due to their Zn levels.
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Figure 14: Box plot comparing the Zn levels from the cadaver sample (COZn) and Kellis (K2Fe).
Summary of Mn Results and Data Trends
A normal range for Mn in humans is 0.26-0.75 μg/g (Miekeley et al., 1998). Of the 28
samples analyzed, 18 samples were found to be outside the normal range. Thirteen samples from
Kellis 2 were found to be above the 0.75 μg/g threshold, and five from the cadaver sample were
below the 0.26 μg/g threshold. The Mn values for the cadaver and the Kellis 2 samples are
recorded in Tables 24 and 25.
For the cadaver sample, only five individuals were outside of the 0.26-0.75 μg/g range,
with four of those being below 0.26 μg/g. The majority of the cadaver samples were found to be
within the normal range. Interestingly, four of the five individuals with confirmed Alzheimer’s
disease displayed normal Mn levels. These individuals are CO-383, CO-422, CO-393, CO-403,
and CO-395. All of these individuals, except CO-395 at 0.25 μg/g, should have Mn levels below
0.26 μg/g due to their Alzheimer’s disease, so it is interesting that their Mn levels show
otherwise. The Mn values for the cadaver samples can be found below in Table 24.
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Table 24: Recorded Manganese (Mn) levels from cadaver samples given in μg/g. Outliers are
denoted with an asterick.
Cadaver
Sample #
CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540
Median #

Sex

Age

F
F
M
F
F
F
F
F
F
M
F
F
F

87
83
80
101
84
79
94
90
97
60
64
64
76

Manganese (Mn)
μg/g
0.62
0.002*
0.34
0.39
0.25*
0.52
0.92*
0.60
0.34
0.28
0.40
0.18*
0.12*
0.34

For the Kellis 2 sample, 13 samples were outside of the normal Mn range of 0.26-0.75
μg/g. Only one sample, K407-4, displayed Mn levels within the normal range at 0.30 μg/g. The
highest Mn level recorded was K2-278 at 7.13 μg/g. Overall, the Mn levels for Kellis 2 samples
are very high when compared to the expected normal Mn range. The Mn values for the Kellis 2
samples are recorded in Table 25.
Manganese was accessible to ancient Egyptians in Kellis primarily as makeup and paint.
Ancient Egyptians used to use kohl and black oxide as a form of eyeliner which contained high
amounts of Mn (Lucas, 1930). Additionally, Mn was also found in the paint of many ceramics
that were made from both synthetic and natural materials (Noll, 1981). Studies show that there’s
a mild to moderate amount of Mn within the western desert of Egypt, however the highest
amounts of Mn found within the natural resources of this area is within the groundwater
(Khozyem et al., 2019; Mohamed et al., 2019). Additionally, purple manganese has been found
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to line many of the burials at the Kellis 2 cemetery, which could have impacted the manganese
values in this study (Tosha Dupras & Lana Williams personal communication, 2021).
Table 25: Recorded Manganese (Mn) levels from Kellis samples given in μg/g
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1
Median #

Sex

Age

M
F
F
F
F
F
N/A
F
M
F
F
F
N/A
F

61
55
55
70
55
55
3 yr
60
60
65
48
20
6 mo
55

Manganese
(Mn) μg/g
2.97*
1.74*
4.84*
6.44*
6.80*
4.32*
7.13*
2.83*
3.04*
5.40*
6.01*
4.29*
0.30
1.48*
4.32

The data for the cadaver Mn samples is normally distributed. The cadaver Mn levels were
1.069 for skewness and 0.712 for kurtosis, showing that they are within the normally distributed
range of -1.96 to 1.96. This information can be found in table 26. Additionally, the p-value for
the cadaver Mn levels is not statistically significant at 0.887, which is greater than the
significance level chosen for this study at 0.05.
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Table 26: Statistics for Cadaver Mn levels

The data for the Kellis 2 Mn samples is normally distributed. The Kellis 2 Mn levels
were -0.544 for skewness and -0.925 for kurtosis, showing that they are within the normally
distributed range of -1.96 and 1.96. This information can be found in table 27. Additionally, the
p-value for the cadaver Mn levels is not statistically significant at 0.418, which is greater than the
significance level chosen for this study at 0.05.
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Table 27: Statistics for Kellis 2 Mn levels

The Mn levels from Kellis 2 are much higher than those of the cadaver sample. Although
both samples have individuals outside of the normal human Mn range, they are both normally
distributed. Figure 16 shows minimal overlap between the two groups, while highlighting the
overall higher Mn levels in Kellis 2. High Mn levels are correlated to periodontal disease,
depression, anxiety, cardiovascular disease, osteoarthritis, diabetes mellitus, and hepatitis C,
while low Mn levels are associated with neurological disorders and fibromyalgia (Wolowiec et
al., 2013; Mikulewicz et al., 2013). Since the Kellis 2 samples primarily display high Mn levels,
it is very possible for the individuals in this sample to have any one of the previously listed
conditions.
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Figure 15: Box plot comparing the Mn levels of the cadaver group (COMn) and Kellis 2 (K2Mn).
Summary of Se Results and Data Trends
Normal Se levels for humans is 0.38-0.70 μg/g (Miekeley et al., 1998). Of the 28 samples
analyzed, 17 individuals have Se levels outside of the normal range. All 16 individuals have Se
levels below 0.38 μg/g, and there are no individuals with Se levels above 0.70 μg/g. The Se
values for the cadaver and the Kellis 2 samples are reported in Tables 28 and 29.
For the cadaver samples, six individuals have Se levels below 0.38 μg/g. Low Se levels
are consistent with neurological diseases like Alzheimer’s disease, however the individuals
diagnosed with AD (CO-383, CO-422, CO-393, and CO-403) all display normal levels of Se.
The only individual diagnosed with AD with abnormal Se levels is CO-395 at 0.285 μg/g. The
lowest Se level recorded is CO-389 at 0.002 μg/g, while the highest is CO-398 at 0.587 μg/g.
The cadaver Se levels are recorded in Table 28.
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Table 28: Recorded Selenium (Se) levels from cadaver samples given in μg/g
Cadaver
Sample #
CO-383
CO-389
CO-393
CO-394
CO-395
CO-398
CO-399
CO-400
CO-403
CO-417
CO-422
CO-528
CO-540
Median #

Sex

Age

F
F
M
F
F
F
F
F
F
M
F
F
F

87
83
80
101
84
79
94
90
97
60
64
64
76

Selenium
(Se) μg/g
0.45
0.002*
0.50
0.35*
0.28*
0.58
0.40
0.36*
0.48
0.30*
0.42
0.33*
0.20*
0.36

Ten individuals from the Kellis 2 sample presented Se levels outside of the normal range
of 0.38-0.70 μg/g. The highest Se level for Kellis 2 is K089-2 at 0.581 μg/g, while the lowest
recorded is K407-4 at 0.122 μg/g. Overall, the Se levels for Kellis 2 are relatively normal with no
peculiarities to note. The Se values for Kellis 2 are recorded in Table 29.
There were not many sources of selenium found in ancient Egypt. There are low amounts
of selenium found in the floodplain soil of the Nile River and relatively low amounts of selenium
within various foods (Moatkhef et al., 2020). Analysis has shown that there were relatively low
amounts of selenium found within local Egyptian fruits such as gates, grapes, and figs.
Additionally, there are relatively low amounts of selenium found within the local nuts and seeds
such as fenugreek, however sesame seeds have a very high content of selenium. Additionally,
selenium levels were found to be very low in rice and local bread of the area, while protein rich
foods such as fish were found to have the highest levels of selenium (Moatkhef et al., 2020).
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Table 29: Recorded Selenium (Se) levels from Kellis samples given in μg/g. Outliers are denoted
with an asterick.
Kellis
Sample #
K089-2
K091-3
K177-1
K261-2
K275-2 A
K275-2 B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4
K528-1
Median #

Sex

Age

M
F
F
F
F
F
N/A
F
M
F
F
F
N/A
F

61
55
55
70
55
55
3 yr
60
60
65
48
20
6 mo
55

Selenium
(Se) μg/g
0.58
0.25*
0.31*
0.28*
0.41
0.27*
0.36*
0.30*
0.31*
0.30*
0.55
0.46
0.12*
0.29*
0.31

The data for the cadaver Se samples is normally distributed. The cadaver Se levels were 1.650 for skewness and 1.673 for kurtosis, showing that they are within the normally distributed
range of -1.96 to 1.96. This information is reported in Table 30. Additionally, the p-value for the
cadaver Se levels is not statistically significant at 0.501, which is greater than the significance
level chosen for this study at 0.05.
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Table 30: Statistics for cadaver Se samples

The data for the Kellis 2 Se samples is normally distributed. The cadaver Se levels were 0.413 for skewness and 0.443 for kurtosis, showing that they are within the normally distributed
range of -1.96 to 1.96. This information can be found in Table 31. Additionally, the p-value for
the Kellis 2 Se levels is not statistically significant at 0.632, which is greater than the
significance level chosen for this study at 0.05.
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Table 31: Statistics for Kellis 2 Se levels

The Se levels in the individuals from Kellis 2 are generally lower than the Se levels from
the cadaver group (Figure 17). Generally, the two groups overlap with the majority of the
samples, aside from the one outlier in the cadaver group, CO-389. Low Se levels are primarily
associated with neurological disorders, while high Se levels are associated with selenosis
(Wolowiec et al., 2013; Mikulewicz et al., 2013). Since there were no abnormally high Se levels
recorded, it is within the scope of possibility that individuals in Kellis 2 suffered from
neurological disorders.
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Figure 16: Box plot comparing the Se levels from the cadaver sample (COSe) and Kellis (K2Se)
Summary of Results
The results from this study show that the individuals from the Kellis 2 cemetery had
elevated levels of Al, Mn, Zn, Fe, and Se in comparison to those from the cadaver sample. Table
50 is a summary of each individuals’ elemental profile from Kellis 2, while table 51 summarizes
the elemental profiles of those from the cadaver sample. Individuals with values that are outside
of the normal range are denoted with an asterisk.
Generally, Al levels amongst the sampled Kellis 2 population are much higher in
comparison to the cadaver sample. The average for the cadaver sample is 8.27 μg/g, while the
average for Kellis 2 is 23.92 μg/g. Only three individuals from the cadaver sample had Al levels
over 12 μg/g, while 10 individuals from Kellis 2 were above 12 μg/g. As stated previously, the
reasoning behind the lowered Al levels for the cadaver group could be explained by the AD
medication some were taking.
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The results for Cu were very interesting in that none of the 28 individuals presented Cu
levels above the threshold of 35 μg/g. 10 individuals from the cadaver sample were below the
threshold of 13 μg/g, while 10 Kellis 2 individuals were below 13 μg/g. Although none of the
samples show Cu levels above 35 μg/g that would be consistent with Alzheimer’s, the Kellis 2
sample did have a much wider range of values at 2.14 – 25.84 μg/g, in comparison to the cadaver
range of 0.08 – 13.89 μg/g.
Six individuals from the cadaver sample had Fe levels outside the normal range of 6-15
μg/g, while 11 individuals from Kellis 2 also had levels that deviated from normal. The highest
value from the Kellis 2 sample was 256.89 μg/g, while the lowest was 8.63 μg/g. The highest
value from the cadaver sample was 19.44 μg/g, while the lowest was 0.05 μg/g. Generally, the
Kellis 2 sample showed more concerning levels of Fe in comparison to the cadaver sample.
Mostly every individual within the cadaver and Kellis 2 sample groups had very low
levels of Zn. All 13 individuals from the cadaver sample had Zn levels below the normal
threshold of 125 μg/g. Additionally, all individuals from the Kellis 2 sample fell outside of the
normal Zn range, with 13 below 125 μg/g and 2 above 165 μg/g.
There were no reported individuals from the sampled Kellis 2 population that had normal
Mn ranges. All 13 individuals from Kellis 2 examined in this study reported values above the
normal threshold of 0.75 μg/g. In contrast, only 5 individuals from the cadaver sample reported
values outside of the threshold, all of which were below 0.26 μg/g. Lastly, 16 individuals
throughout the two sample groups displayed abnormal Se levels that deviated from the normal
range. There were seven individuals from the cadaver sample that showed Se levels below the
normal threshold of 0.38 μg/g, while ten individuals from Kellis 2 were also below the threshold
of 0.38 μg/g.
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Table 32: Summary of element values from the Kellis 2 sample provided in μg/g. Outliers are
denoted with an asterick.
Kellis
Sample
#

Est.
Sex

Est.
Age

Aluminu
m (Al)
μg/g

Copper
(Cu)
μg/g

K089-2
K091-3
K177-1
K261-2
K275-2
A
K275-2
B
K2-278
K280-1
K281-1
K306-4
K2-398
K2-403
K407-4

M
F
F
F
F

61
55
55
70
55

14.85*
8.71
25.21*
43.44*
14.60*

4.86*
8.21*
24.95
2.14*
6.94*

Mangan
ese
(Mn)
μg/g
256.89*
2.97*
13.97
1.74*
63.46*
4.84*
59.97*
6.44*
31.44*
6.80*

F

55

27.37*

14.60

24.42*

N/A
F
M
F
F
F
N/A

9.07
29.41*
16.32*
N/A
94.75*
4.66
13.31*

9.26*
4.02*
3.68*
5.22*
25.84
11.70*
19.01

K528-1

F

3 yr
60
60
65
48
20
6
mo
55

14.03*

2.15
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Iron
(Fe)
μg/g

Seleniu
m (Se)
μg/g

Zinc
(Zn)
μg/g

0.58
0.25*
0.31*
0.28*
0.41

11.55*
34.45*
381.69*
15.75*
24.68*

4.32*

0.27*

10.76*

43.10*
47.91*
23.19*
79.41*
54.38*
11.55
8.63

7.13*
2.83*
3.04*
5.40*
6.01*
4.29*
0.30

0.36*
0.30*
0.31*
0.30*
0.55
0.46
0.12*

24.42*
15.11*
21.53*
11.62*
44.82*
24.30*
567.91*

15.10

1.48*

0.29*

15.01*

Table 33: Summary of element values from the Cadaver sample provided in μg/g. Outliers are
denoted with an asterick.
Cadaver Sex Age Aluminum
Sample
(Al) μg/g
#
CO-383
F
87
22.15*
CO-389
F
83
0.02
CO-393
M
80
4.00
CO-394
F 101
9.04
CO-395
F
84
3.18
CO-398
F
79
6.83
CO-399
F
94
14.67*
CO-400
F
90
17.00*
CO-403
F
97
10.29
CO-417
M
60
6.14
CO-422
F
64
8.06
CO-528
F
64
3.59
CO-540
F
76
2.57

Copper
(Cu)
μg/g
4.50*
0.08*
10.43*
5.89*
6.47*
14.56
9.48*
13.67
13.89
12.22*
8.11*
5.76*
3.48*
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Iron Manganese Selenium
(Fe)
(Mn) μg/g (Se) μg/g
μg/g
19.44
0.62
0.45
0.05
0.002
0.002
6.61
0.34
0.50
13.63
0.39
0.35
4.97
0.25
0.28
9.84
0.52
0.58
24.20
0.92
0.40
18.76
0.60
0.36
8.20
0.34
0.48
7.75
0.28
0.30
15.82
0.40
0.42
11.13
0.18
0.33
5.54
0.12
0.20

Zinc
(Zn)
μg/g
27.12*
0.17*
34.52*
26.38*
27.06*
30.13*
37.81*
41.91*
38.63*
13.81*
31.79*
29.26*
18.66*

CHAPTER FIVE:
DISCUSSION
This study was designed to develop a more in-depth analysis and understanding of
neurological diseases and disorders in the past. Previous trace element analyses examine soft
tissue diseases such as cardiovascular disease (Houtman, 1996), kidney and liver disease
(Davenport, 2015; Loguercio et al., 1997), and diabetes (Praveeena et al., 2013), to name a few.
There are no studies, however, that attempt to detect neurodegenerative diseases within the
archaeological record. While trace element analysis provides researchers with a realistic idea of
an individual’s biology, it cannot be used as a definitive diagnostic tool. This should be kept in
mind throughout the forthcoming sections of this discussion.
To determine the presence of disease(s), it is important to reference what a “normal”
trace element profile looks like in the average adult. Emphasis is placed on the word “normal”
because while this information is regarded within the scientific community as accurate and
factual, it is not necessarily ubiquitous. The word “normal” is a very relative and subjective term,
so while Table 34 is reflective of a “normal” trace element profile within an average adult, there
will always be variation when dealing with human biology. The profile created by Miekeley et
al. (1998) is used as a reference in this study since it is the most widely used and accepted form
of a “baseline” within the scientific community today.
Table 34: Reference values outlined by Miekeley et al. (1998) for a “normal” trace element
profile within an average adult
Trace Elements

Normal Range
(μg/g)
< 12 μg/g
13 – 35 μg/g
6 – 15 μg/g
0.26 – 0.75 μg/g
0.38 – 0.70 μg/g
125 – 165 μg/g

Aluminum (Al)
Copper (Cu)
Iron (Fe)
Manganese (Mn)
Selenium (Se)
Zinc (Zn)
100

Additionally, to assess the health of the individuals from Kellis, it is essential to have an
understanding of how abnormal trace element values can affect an individual’s biology. Table 35
outlines the various diseases that may manifest when an individual has “too much” or “too little”
of an essential element. This information is necessary to assess the presence of neurological
disorders, as well as any possible co-morbidities. While this table is helpful in the assessment of
health and disease, it is important to remember that these references are not universal to all
humans. For example, if an individual is presenting abnormally high Al levels above 12 μg/g,
they have the possibility of developing neurological disorders, cardiovascular disease, and/or
kidney & liver disease; however, there is a chance that while the individual has a high Al level,
they did not develop any of the aforementioned diseases. Human biology is tricky in that there is
not a universal blueprint for health and disease. This information should be kept in mind moving
forward through the discussion.
Table 35: In depth review of possible diseases and disorders that can manifest if the trace
elements were to deviate from normal. Adapted from (Wolowiec et al., 2013; Mikulewicz et al.,
2013)
High Aluminum

Low Aluminum 
High Copper 
Low Copper 
High Iron 
Low Iron 
High Manganese

Low Manganese

High Selenium 
Low Selenium 

Neurological disorders; cardiovascular disease; kidney & liver
disease
Multiple sclerosis; Neurological disorders
Neurological disorders; periodontal disease; metabolic disorder
Neurological disease; Breast cancer; stroke; liver cirrhosis;
cardiovascular disease; anemia
Neurological disorders; kidney & liver diseases; breast cancer;
periodontal disease; multiple sclerosis; osteoarthritis; diabetes
mellitus
Stroke; anemia; fibromyalgia; metabolic disorder
Periodontal disease; depression/anxiety; stroke; cardiovascular
disease; osteoarthritis; diabetes mellitus; hepatitis C
Neurological disorders; fibromyalgia
Stroke; selenosis
Neurological disorders
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High Zinc 
Low Zinc 

Periodontal disease; stroke; ADHD; osteoarthritis; diabetes mellitus;
hepatitis C
Neurological disorders; anemia; cancer (general); cardiovascular
disease; liver cirrhosis

Lastly, Table 36 details the specifics of each archaeological sample from Kellis. The
sample number, element profile, skeletal information, and possible disease(s) are outlined.
Values that are bolded within each respective element profile are values that are outside of the
normal range outlined by Miekeley et al. (1998). Since this study is focused on determining the
presence of neurological diseases, specifically Alzheimer’s, the forthcoming discussion will
focus on the eight individuals who present possible neurological disorders. The additional five
individuals, K2-403, K2-278, K407-4, K528-1, and K091-3 do not present any signs of
neurological disorders and will be excluded from the discussion, although they are referenced in
Table 36.

Table 36: Summary of information from Kellis 2 archaeological samples. Skeletal information
provided by Dr. Lana Williams
Sample
#
K089-2

Hair Trace
Element Profile
Al 14.85
Cu 4.87
Fe 256.90
Mn 2.97
Se 0.58
Zn 11.56

Estimated
Sex
M

Estimated
Age
61

K091-3

Al 8.71
Cu 8.22
Fe 13.97
Mn 1.74
Se 0.26
Zn 34.45

F

55

102

Skeletal Information
osteoarthritis;
ankylosing of
sacroiliacs & T6-L4;
lytic lesion in right
orbit; healed fracture
of right 2nd rib;
bilateral
chondromalacia of
patellae
very osteoporotic;
small osteomas on
frontal; spina bifida
occulta of S1-3;
bilateral
chondromalacia in
patellae

Possible
Disease(s)
Neurological
disease;
kidney/liver
disease; diabetes
mellitus;
cardiovascular
disease; anemia

Anemia; stroke;
cardiovascular
disease;
osteoarthritis

Sample
#
K177-1

Hair Trace
Element Profile
Al 25.21
Cu 24.95
Fe 63.46
Mn 4.84
Se 0.32
Zn 381.70

Estimated
Sex
F

Estimated
Age
55

Skeletal Information

K261-2

Al 43.44
Cu 2.15
Fe 59.97
Mn 6.45
Se 0.28
Zn 15.76

F

70

osteoporosis; healed
fractures on femoral
neck, T12, & L1;
advanced spinal
degeneration

K275-2
A+B

Al 14.50, 27.28
Cu 6.94, 14.60
Fe 31.44, 24.43
Mn 6.81, 4.33
Se 0.41, 0.27
Zn 24.68, 10.76

F

55

No indications visible

K2-278

Al 9.07
Cu 9.27
Fe 43.11
Mn 7.14
Se 0.36
Zn 24.42
Al 29.41
Cu 4.03
Fe 47.91
Mn 2.84
Se 0.31
Zn 15.11

N/A

3 yr

Plane defects on
deciduous maxillary
canines

F

60

osteoporosis; healed
bilateral ulnar
fractures; osteolytic
lesions on cranial vault
& C1-T2; TB

Al 16.33
Cu 3.69
Fe 23.19
Mn 3.04
Se 0.32
Zn 21.54

M

60

osteoporosis;
periosteal reaction on
lower limbs; healed
fractures of C6, T1 &
L4; healed nasal
fracture

K280-1

K281-1
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osteoporosis of lower
thoracic & lumbar

Possible
Disease(s)
Neurological
disease;
kidney/liver
disease;
periodontal
disease; cancer;
osteoarthritis;
diabetes mellitus
Neurological
disease;
kidney/liver
disease; anemia;
cardiovascular
disease; diabetes
mellitus;
osteoarthritis;
cancer
Neurological
disease;
kidney/liver
disease;
cardiovascular
disease;
periodontal
disease; anemia;
diabetes mellitus
Periodontal
disease; diabetes
mellitus; anemia

Neurological
disease;
kidney/liver
disease; anemia;
cardiovascular
disease;
osteoarthritis
Neurological
disease;
kidney/liver
disease; anemia;
cardiovascular
disease; diabetes
mellitus;
osteoarthritis;
cancer

Sample
#
K306-4

Hair Trace
Element Profile
Al N/A
Cu 5.23
Fe 79.41
Mn 5.40
Se 0.31
Zn 11.62

Estimated
Sex
F

Estimated
Age
65

Skeletal Information

K2-398

Al 94.75
Cu 25.84
Fe 54.38
Mn 6.01
Se 0.55
Zn 44.98
Al 4.67
Cu 11.71
Fe 11.55
Mn 4.29
Se 0.47
Zn 24.04
Al 13.31
Cu 19.01
Fe 8.63
Mn 0.30
Se 0.12
Zn 567.92
Al 14.03
Cu 2.16
Fe 15.10
Mn 1.48
Se 0.30
Zn 15.02

F

48

No indications visible

F

20

No indications visible

Anemia;
cardiovascular
disease; diabetes
mellitus;

N/A

6 mo

No indications visible

Cancer; diabetes
mellitus;
hepatitis C

F

55

osteoporosis;
degenerative changes
in knees; healed
clavicle fracture

Osteoarthritis;
cardiovascular
disease; anemia;
stroke

K2-403

K407-4

K528-1

osteoporosis;
degenerative changes
in knees; smorl’s
nodes on T4, T7, T8;
T12 vertebral centrum
resorbed

Possible
Disease(s)
Neurological
disease; diabetes
mellitus;
kidney/liver
disease; cancer;
osteoarthritis;
anemia;
periodontal
disease
Neurological
disease;
cardiovascular
disease; anemic

Determining the Presence of Neurological Disease
K2-398
Individual K2-398 is a 48-year-old female with no visible skeletal pathology or trauma.
She has a very high level of Al at 94.76 μg/g, normal Cu levels at 25.84 μg/g, high Fe at 54.38
μg/g, extremely high Mn at 6.02 μg/g, normal Se at 0.56 μg/g, and very low Zn at 44.82 μg/g.
This individual does not show signs of Wilson’s disease since there is not a drastic increase in
Cu levels. Additionally, the extremely high Al levels eliminate autism, ALS, and down’s
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syndrome. The high levels of Fe and Cu eliminate any possible mood disorder as well as
Huntington’s disease. Although K2-398 aligns relatively well with prion disease and epilepsy
due to the low level of Zn and the increase in Mn, it is difficult to determine if she had either of
these two diseases since we do not have information on Al, Fe, or Se levels for prion disease and
epilepsy.
The differential diagnosis of this individual indicates that they may have suffered from
either Parkinson’s disease (PD) or Alzheimer’s disease (AD). As stated previously, the elemental
profile for AD shows an increase in Al, Cu, and Fe, with a decrease in Mn, Se, and Zn. For PD,
there is generally an increase in Al, Fe, Mn, Se, and Zn, with a decrease in Cu. However, the Cu
levels for this individual are considered to be within the range of normal at 25.84 μg/g. Although
she reflects the profile of someone with Parkinson’s disease, that is not enough reason to
eliminate Alzheimer’s disease altogether due to the possibility of co-morbidities. If she had
Alzheimer’s disease, her extremely high Mn levels could be explained by a heart, liver, or kidney
disease. This hypothesis is also supported by her high levels of Al and Fe which align with
cardiovascular disease and possible kidney or liver disease. Additionally, due to her extremely
low Zn levels, she could have possibly been anemic which would support the hypothesis that she
had some kind of cardiovascular disease in conjunction with a neurological disease.

K177-1
Individual K177-1 is a 55-year-old female with osteoporosis of the lower thoracic and
lumbar vertebrae. She shows no signs of skeletal trauma or pathology other than the vertebral
osteoporosis. She has a high level of Al at 25.21 μg/g, normal Cu levels at 24.95 μg/g, high Fe at
63.46 μg/g, extremely high Mn at 4.84 μg/g, low Se at 0.32 μg/g, and extremely high Zn at
381.70 μg/g. This individual does not fit the profile of someone with autism, down’s syndrome,
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or ALS since she has a high level of Al. Additionally, she most likely does not have Alzheimer’s
disease, Huntington’s disease, Prion disease, epilepsy, or a mood disorder since she has an
extremely high level of Zn.
This individual may have had early onset Parkinson’s disease; however, her Cu and Se
levels do not align with the typical profile of someone with Parkinson’s. Although her Se levels
are lower than the average range, the values are not statistically significant and do not warrant
excluding Parkinson’s since her Se level is only 0.06 μg/g below “normal.” The peculiarity with
K177-1 is her extremely high Zn level of 381.70 μg/g. As of recently, researchers have been
using high doses of Zn to treat cancer patients in an effort to offset their low Zn levels caused by
the cancer. With this idea of using high amounts of Zn to treat cancer, we can assume that
individuals with low Zn may possibly have cancer or are susceptible to developing cancer.
Additionally, her high levels of Fe and Mn point to the possibility of diabetes; however,
Wolfgang Maret (2013) explains that researchers have found lowered Zn levels in their type 1
and type 2 diabetic patients due to the increased loss of Zn in urine. This information rules out
the possibility of diabetes, however that does not exclude kidney disease altogether. Since high
Zn levels over 165 μg/g is consistent with Parkinson’s, it is possible that she may have had early
onset PD, kidney disease, and/or cardiovascular disease. This information is consistent with the
lack of skeletal pathology or trauma found on K177-1 aside from osteoporosis on the thoracic
and lumbar vertebrae.

K280-1
Individual K280-1 is a 60-year-old female with osteoporosis, healed bilateral ulnar
fractures, tuberculosis, and osteolytic lesions on cranial vault as well as C1-T2. She has high
levels of Al at 29.41 μg/g, low Cu at 4.03 μg/g, high Fe at 47.91 μg/g, high Mn at 2.84 μg/g, low
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Se at 0.31 μg/g, and extremely low Zn at 15.11 μg/g. The high levels of Al rule out autism,
Down’s syndrome, and ALS. She is also not presenting signs of AD, Wilson’s disease, epilepsy,
or mood disorders due to her low level of Cu, high Mn, and high Fe. This leaves Parkinson’s
disease and prion disease; however, neither of these diseases fit perfectly with individual K2801’s trace element profile. She may not have Parkinson’s disease due to her extremely low Zn
levels, however this could be explained by co-morbidities. She could have prion disease, yet Al
and Se levels are unknown for individuals with this disease. Prion disease is very rare, affecting
1-2 people per million across the globe, which also minimizes the possibility of her having this
disease.
The trace element profile for individual K280-1 is consistent with someone who has
cardiovascular disease, anemia, liver and/or kidney disease. High levels of Al and Mn in
conjunction with low Cu are consistent with cardiovascular disease, while low Zn and Cu are
congruent with anemia. Lastly, high Al, Fe and Mn in association with low Cu present issues
with the liver and kidneys. Low Cu and Zn are consistent with cancer, and a diagnosis of
metastatic carcinoma would explain the osteolytic lesions on the cranial vault. Although the
determination of neurological disease for K280-1 is difficult, she most likely had anemia coupled
with heart, liver, and/or kidney issues.

K281-1
Individual K281-1 is a 60-year-old male with osteoporosis, periosteal reaction on the
lower limbs, healed fractures on C6, T1, and L4, and a healed nasal fracture. He has a high level
of Al at 16.33 μg/g, low Cu at 3.69 μg/g, relatively high Fe at 23.19 μg/g, high Mn at 3.04 μg/g,
low Se at 0.32 μg/g, and low Zn at 21.54 μg/g. The high levels of Al rule out autism, down’s
syndrome, and ALS. His profile does not suggest AD, Wilson’s disease, epilepsy, or mood
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disorders due to his low level of Cu, high Mn, and high Fe. This leaves Parkinson’s disease and
prion disease; however, neither of these diseases fit perfectly with his trace element profile. He
may not have Parkinson’s disease due to his extremely low Zn levels, however this could be
explained by co-morbidities. He could have prion disease, yet Al and Se levels are unknown for
individuals with this disease. Prion disease is very rare, affecting 1-2 people per million across
the globe, which also minimizes the possibility of him having this disease.
The element profile for K281-1 aligns with someone who has cancer, anemia,
cardiovascular disease, and/or kidney and liver disease. Unlike K280-1, he does not show any
skeletal indications of cancer; however, he could have suffered from a soft tissue cancer that
does not metastasize to the bone. This would exclude the latter stages of lung and prostate
cancer. In addition to the possible prognosis of cancer, low Zn and Cu levels indicate anemia.
Anemia is frequently associated with various cardiovascular diseases, which is supported by the
high levels of Al and Mn and the low levels of Cu and Zn. Lastly, high levels of Al, Fe, and Mn
accompanied with low levels of Cu point towards a kidney and/or liver disease. However, in the
case of K281-1, he most likely has liver cirrhosis due to the low levels of Cu and Zn. Much like
K280-1, it is difficult to determine if or what neurological disease K281-1 may have, however it
is likely that he may not have suffered from a neurological disease but suffered from liver
cirrhosis, cardiovascular disease, and/or anemia.

K261-2
Individual K261-2 is a 70-year-old female with osteoporosis, healed fractures on the
femoral head, T12, and L1, in addition to advanced spinal degeneration. She has very high Al
levels at 43.44 μg/g, low Cu at 2.15 μg/g, high Fe at 59.97 μg/g, extremely high Mn at 6.45 μg/g,
low Se at 0.28 μg/g, and extremely low Zn at 15.76 μg/g. Wilson’s disease, autism, epilepsy,
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mood disorder(s), and Down’s syndrome have been eliminated due to the extremely high levels
of Al and Mn and the low level of Cu. Additionally, K261-2 does not appear to have
Alzheimer’s disease since she has a very low level of Cu accompanied with an extremely high
level of Mn.
Parkinson’s disease could be a contender, however her low levels of Se and Zn go against
the typical trace element profile of an individual with Parkinson’s. Nonetheless, she could have
Parkinson’s disease and the low levels of Se and Zn could be explained by simple human
variation or co-morbidities. Building on this, Huntington’s disease may also fit the differential
diagnosis. Her trace element profile fits well with the typical profile seen in Huntington’s disease
patients, aside from her very high Mn level. As stated previously, this could be explained by
human variation since there is no “set” trace element profile for these diseases. Patients with
Parkinson’s disease and Huntington’s disease have been known to suffer from spinal
degeneration, which could offer an explanation for the advanced spinal degeneration recorded
for this individual (Muhlau et al., 2014; Farnikova et al., 2012).
As the oldest individual within the Kellis 2 archaeological sample, it’s likely that she
suffered from a neurological disease in addition to other health concerns. With an Al level of
43.44 μg/g it is likely that she suffered from some kind of cardiovascular disease. When
referencing the cadaver samples from this study, the individuals with the highest Al levels had
neurological diseases coupled with cardiovascular issues. For example, cadaver sample CO-383
had an Al level of 22.15 μg/g and suffered from treated Alzheimer’s disease and
cardiopulmonary arrest. It is likely that her Al levels were much higher before she began
treatment for Alzheimer’s disease since medication inhibits the uptake of Al and Cu.
Additionally, CO-400 had an Al level of 17.00 μg/g and suffered from a thoracic aortic aneurysm
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and peripheral artery disease. CO-383 and CO-400 presented high levels of Al and Fe
accompanied by low levels of Cu, Mn, and Zn. Aside from the low Mn, CO-383 and CO-400
share a very similar element profile with K261-1, which leads to the conclusion that she may
have suffered from cardiovascular disease in addition to Parkinson’s disease or Huntington’s
disease.

K089-2
Individual K089-2 is a 61-year-old male with osteoarthritis, ankylosing of the sacroiliacs
and T6-L4, osteolytic lesion in the right eye orbit, a healed fracture of the second right rib, and
bilateral chondromalacia of the patellae. He has high Al levels at 14.85 μg/g, low Cu at 4.87
μg/g, extremely high Fe at 256.90 μg/g, high Mn at 2.97 μg/g, normal Se at 0.58 μg/g, and
extremely low Zn at 11.56 μg/g.
The most noteworthy aspect of individual K089-2’s trace element profile is the extremely
high level of Fe at 256.90 μg/g, which is 17 times the normal amount of Fe for an adult. The high
amount of Fe would indicate that he suffered from cancer that metastasized to the bone, as
demonstrated by the lytic lesion in the right eye orbit. Since the skeletal remains of K089-2 do
not show any skeletal signs of cancer aside from the right eye orbit, he most likely suffered from
a soft tissue cancer such as lung or prostate cancer. Researchers have found that high levels of Fe
contribute to the damage of cellular structures, aging, and cancer development (Eaton & Qian,
2002), which further supports the hypothesis that K089-2 suffered from a soft tissue cancer
(Torti and Torti, 2020). Additionally, his low levels of Cu and Zn support the hypothesis that he
suffered from a soft tissue cancer.
Although individual K089-2 presents a trace element profile that aligns with the
possibility of a neurological disease, his trace element profile supports the hypothesis that he
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suffered from cancer and ankylosing spondylitis rather than a neurological disease. His Al level
is not drastically high, with only a 2.87 μg/g deviation from normal, which leads to the
conclusion that his Al level may have contributed to another issue such as kidney and liver
disease. This hypothesis would also align with the very high Fe level, which could have also
affected his kidney and liver since Fe is critical for the function of those organs. It is not outside
the scope of possibility that he may have suffered from cancer of the kidney or liver, which
would explain the high Fe and Al in addition to the low levels of Cu and Zn.

K306-4
Individual K306-4 is a 65-year-old female with osteoporosis, smorl’s nodes on T4, T7,
and T8, vertebral centrum resorbed on T12, and degenerative changes in both knees. She has low
Cu levels at 5.23 μg/g, high Fe at 79.41 μg/g, extremely high Mn at 5.40 μg/g, low Se at 0.31
μg/g, and very low Zn at 11.62 μg/g. ICP-MS was unable to generate Al level for K306-4, so that
information is not included in this analysis. This is because the Al value for K306-4 was either
too far below the limit of detection or too far above the calibration curve, making the
concentration questionable at best. Without knowing K306-4’s Al level it is difficult to generate
a diagnosis, however based on the rest of her trace element profile, we can assume that she did
not have Wilson’s disease, Alzheimer’s disease, epilepsy, or a mood disorder due to her low Cu
level. Additionally, she most likely did not have autism or ALS due to her high Fe and Mn
levels. It is likely that she did not have Parkinson’s disease due to her low levels of Se and Zn,
however this cannot be confirmed since we do not know her Al level. Also, she appears to fit
within the profile for Huntington’s disease, but again, this cannot be confirmed because her Al
level is unknown.
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Although the differential diagnosis of a neurological disease cannot be completed,
individual K306-4 most likely suffered from kidney, liver, and/or heart issues. Her low levels of
Cu and Zn coupled with high Fe point towards kidney and liver issues. Additionally, her low Cu
and Zn in conjunction with high Mn indicate cardiovascular issues. Her skeleton shows general
signs of aging with no major indication of disease, which leads to the conclusion that she
suffered from complications of the soft tissue. Building on this, she may have suffered from
cancer, specifically breast cancer. Low Cu and Zn along with high Fe are congruent with breast
cancer that has not metastasized to the bone (Wolowiec et al., 2013; Czerny et al., 2014).
However, it is within the scope of possibility that she suffered from cancer of the liver, kidney,
or heart rather than breast cancer.

K275-2 A+B
Individual K275-2 is a 55-year-old female with no visible skeletal pathology or trauma.
The hair from K275-2 was cut into two pieces to reflect the changes of trace element
concentrations along the hair shaft, however the element concentrations are relatively the same
amongst the two samples. The values for K275-2 A will be listed first, and K275-2 B will be
listed second. Her Al levels are 14.50 and 27.28 μg/g, relatively normal Cu at 6.94 and 14.60
μg/g, high Fe at 31.44 and 24.43 μg/g, very high Mn at 6.81 and 4.33 μg/g, relatively normal Se
at 0.41 and 0.27 μg/g, and extremely low Zn at 24.68 and 10.76 μg/g.
Wilson’s disease, autism, epilepsy, Alzheimer’s disease, and Down’s syndrome have
been eliminated due to the combination of high Al, low Cu, normal Fe, and high Mn. She
displays the same trace element profile as someone with Prion disease, yet the rarity of Prion
disease makes the likelihood of K275-2 suffering from this disease very low. Lastly, while her
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Al, Cu, Fe, and Mn levels are aligned with Parkinson’s disease, her extremely low Zn levels and
normal Se levels support that she may not have suffered from Parkinson’s.
Individual K275-2 may have suffered from a mood disorder such as depression or
anxiety. While studies have shown that individuals with mood disorders have increased Cu
levels, the cadaver samples used in this study conflict with that idea. CO-540 and CO-403
suffered from depression in addition to other health issues. CO-540 shows a Cu level of 3.48
μg/g and CO-403’s Cu level is 13.89 μg/g. The Cu levels of CO-540 and CO-403 match the
general trend of low and normal Cu levels displayed by K275-2, which leads to the hypothesis
that she may have suffered from some type of mood disorder. This is supported by her extremely
high Mn levels, which are typically indicative of depression and/or anxiety.
Individual K275-2’s extremely high Mn levels are worth exploring further since she has
the second highest Mn levels recorded within either group, behind K2-278 at 7.14 μg/g. High Mn
levels are typically indicative of depression, anxiety, stroke, cardiovascular disease,
osteoarthritis, diabetes mellitus, hepatitis C, and periodontal disease (Wolowiec et al., 2013;
Mikulewicz et al., 2013). Since K275-2 died at approximately 55 years of age with no skeletal
indications of trauma or pathology, it is safe to assume that she most likely suffered from a soft
tissue disease. High Al and Mn accompanied by low Cu and Zn generally point towards heart,
kidney, and liver diseases. Miao et al. (2013) explains that individuals with T1 or T2 diabetes
tend to have depleted Zn levels, which would support the hypothesis that she suffered from a soft
tissue disease, such as diabetes mellitus.

Implementing the Bioarchaeology of Care Index
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The bioarchaeology of care index was created as a method to understand health and
disability in the past (Tilley, 2012). The bioarchaeology of care index should not be used as a
definative tool to contextualize medical treatment in the past, andand there are built-in
mechanisms to dissuade the use of broad overarching statements regarding care in the past. The
forthcoming discussion will break down the details of each step outlined by Tilley (2012) to
create a meaningful discussion about the medical practices at Kellis. While we will never
definatively know if the people of Kellis suffered from these ailments, we can still generate a
possible model of care that the people in this community may have implimented to assist the
elderly population.

Step One: Determine, Diagnose, and Document
The first step of the Index of Care is to determine, diagnose, and document individual
pathology. Table 53 below provides a detailed account of the skeletal trauma and pathology
documented from the 13 individualsanalyzed in this study. A number of these pathological
conditions are debilitating, For example, individual K089-2 shows skeletal indicators of
ankylosing spondilitis of the sacroiliacs and T6-L4 vertebrae. This condition involves the fusion
of the vertebrae which limits range of motion, increases back pain, and weakens bone mass.
Additionally, a number of individuals, such as K280-1, K281-1, K089-2, K261-2, and more
show skeletal indications of antemortem tooth loss. This would significantly impact their intake
of food and could possibly lead to poor nutrition if they were not properly cared for.

Table 37: Macroscopic skeletal information of the 13 individuals from Kellis 2
Kellis
Estimated
Sample Sex
#
K089-2 M

Estimated
Age

Kellis Individual Information

61

Considerable OA; ankylosing of sacroiliacs & T6-L4
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Kellis
Estimated
Sample Sex
#

Estimated
Age

K091-3 F

55

K177-1 F

55

K261-2 F

70

K275-2 F
A+B
K2-278 N/A

55

K280-1 F

60

K281-1 M

60

K306-4 F

65

K2-398
K2-403
K407-4
K528-1

48
20
6 mo
55

F
F
N/A
F

3 yr

Kellis Individual Information

vertebrae; lytic lesion in right orbit (trachoma?); healed
fracture of right 2nd rib; bilateral chondromalacia of
patellae; 10 teeth lost antemortem
Very osteoporotic; 11 mandibular teeth lost
antemortem; small osteomas on frontal; spina bifida
occulta of S1-S3; bilateral chondromalacia in patellae
Osteoporosis of lower thoracic & lumbar vertebrae; 14
teeth lost antemortem
From previous TE study: Endocrine and/or organ
dysfunction (e.g., estrogen, brain/liver/kidney)
Osteoporosis; healed fracture of femoral neck & T12-L
1 vertebrae; advanced degenerative changes in spine;
22 teeth lost antemortem
No indications visible
DEH - Plane defects on deciduous maxillary canines right canine has single oblong pit & left side has 3
clustered pits; no other lesions visible
Osteoporosis; well-healed bilateral ulnar fractures;
osteolytic lesions on cranial vault & C1-T2 vertebrae;
tuberculosis; 22 teeth lost antemortem
From previous TE study: Endocrine and/or organ
dysfunction (e.g., estrogen, brain/liver/kidney),
Immune response dysfunction (e.g. cancer,
tuberculosis)
Slight osteoporosis; periosteal reaction on lower limb
bones & radii; well-healed fractures of C6, T1 & L4
vertebrae; healed nasal fracture; 21 teeth lost
antemortem
Slight osteoporosis; degenerative changes in knees;
Smorl's nodes on T4, T7-T8; T12 vertebral centrum
resorbed (septicemia/tuberculosis?) 21 teeth lost
antemortem
From previous TE study: Endocrine dysfunction (e.g.,
estrogen), Immune response dysfunction (e.g. cancer,
tuberculosis)
No indications visible
No indications visible
No indications visible
Severe osteoporosis; degenerative changes in knees;
healed fracture of clavicle
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While the skeletal information provided in Table 53 is enough to argue for the presence
of individual pathological conditions, the purpose of this study is to determine the presence of
neurological disease and understand the care provided to those with these diseases. Seven out of
the eight individuals examined for neurological diseases had a trace element profile that was
consistent with the presence of a neurological disease. K089-2 was the only individual from the
group of eight whose profile was not consistent with any of the neurological diseases being
examined in this study. The information provided in Tables 53 and 54 are enough to warrant
substantial evidence for serious, and possibly debilitating, pathological conditions.

116

Table 38: Differential diagnoses for individuals who presented trace element profiles consistent
with possible neurological diseases
Kellis
Sample
#
K089-2

Estimated
Sex

Estimated
Age

Possible Diseases (Neurological and other)

M

61

K177-1

F

55

Kidney/liver issues; Cancer; Likely had no neurological
diseases
Parkinson’s disease; Heart/kidney issues

K261-2

F

70

K280-1

F

60

K281-1

M

60

K306-4

F

65

K2-398

F

48

K275-2

F

55

Huntington’s
disease
or
Parkinson’s
disease;
Cardiovascular issues
Heart/liver/kidney issues; Anemia; Parkinson’s disease
or Prion disease; Cancer
Anemia; Cancer; Heart/liver/kidney issues (possibly
liver cirrhosis); Parkinson’s disease or Prion disease
Huntington’s
disease
or
Parkinson’s
disease;
Heart/liver/kidney issues; Cancer
Parkinson’s
disease
or
Alzheimer’s
disease;
Heart/kidney/liver issues; anemia
Mood disorder; Kidney/liver issues (possibly diabetes)

Step Two: Assessing Probability of Care Provision
Step two of the Index of Care requires an in-depth understanding of how the
aforementioned pathologies affect the individual’s ability to carry out everyday tasks, both
within and outside of the home sphere. Additionally, this step is dedicated to understanding if
assistance would be needed on a daily basis to help alleviate the burden of the pathology. The
neurological diseases identified within the Kellis sample are Parkinson’s disease, Alzheimer’s
disease, Huntington’s disease, Prion disease, and mood disorder(s).
Broadly, Alzheimer’s disease, Parkinson’s disease, Prion disease, and Huntington’s
disease generally display the same symptoms. All three diseases involve the physical and mental
degeneration followed by pre-mature death (Maresova et al., 2016). Generally, individuals with
these diseases have issues with decision-making, counting, remembering, learning,
understanding, and communicating (Burns, 2000). Additionally, these neurological diseases are
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characterized by impaired motor functions, autonomic dysfunctions, neuropsychiatric issues,
sleep disorders, and dementia (Prizer and Browner, 2012). Van Der Marck (2009) outlines more
specific symptoms that include resting tremor, rigidity, akinesia, and gait impairment. As the
disease begins to progress, these symptoms become more debilitating.
The typical demands of Alzheimer’s, Parkinson’s, Prion disease, and Huntington’s
disease involve the acknowledgement of symptoms, dealing with new emotions surrounding the
disease, finding proper medical treatment and care, living with a constantly changing body, and
dealing with unpredictability (Habermann, 1996). When an individual is diagnosed with one of
these neurological diseases, it is indicative that their body is no longer functioning properly.
Basic everyday tasks are now seen as monumental chores that diminish their individualism.
Examples of this outlined by Habermann (1996) include tasks such as walking or squeezing a
tube of toothpaste. Prizer and Browner (2012) argue that the care and treatment of individuals
with these neurological diseases requires more than an at-home caregiver. This typically involves
a neurologist, physical therapist, occupational therapist, speech therapist, and a social worker.
Since the care for patients with Alzheimer’s, Parkinson’s, and Huntington’s disease is so
involved, this indicates that care for these patients require communal support.
Due to the high prevalence of these neurological diseases, many studies have been
conducted to understand how the caregivers are affected by their positions. Maresova et al.
(2016) explains that roughly 63% of individuals who were below the retirement age either quit
their jobs or reduced their work hours below 20 a week to provide care for their loved ones with
Alzheimer’s disease. They further the discussion by stating roughly 69% of caregivers spend on
average 14 hours a day caring for their loved one with Alzheimer’s disease.
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Callahan and colleagues (2014) developed a list of components involved in the care of
patients with degenerative neurological diseases. Components involved are: 1) a formal
diagnosis, 2) evaluate any treatable causes of cognitive decline, 3) involve a primary care
physician as well as a specialist, 4) daily assessment of physical and mental issues of patient to
train the caregiver in management and identification of these behaviors, 5) discuss the goals of
care giving, 6) create a list of medications to help alleviate symptoms, 7) promote consistent
physical, cognitive, and social activity within the community, 8) take care of any possible comorbidities experienced by the patient within the context of the neurological disease, and 9)
record patient progress and adjust care goals if needed. The list outlined by Callahan and
colleagues (2014) is a very exhaustive list, however it is an accurate account of the daily realities
of caring for someone with a neurological disease.
Based on the clinical information presented within this section, the debilitating nature of
degenerative neurological diseases such as Parkinson’s, Alzheimer’s, Prion disease, or
Huntington’s disease affirm the notion that these individuals from Kellis required care from
others within their community.

Step Three: Developing a Model of Care
Medicine within ancient Egypt was vast and evolved continually over the millennia. As
stated in Chapter 2, ancient Egyptians had a vast medical system and is considered by many to be
the birthplace of neuroscience (Stern, 1989). Nasser (1987) explains that ancient Egyptians
referred to medicine as “a necessary art.” Part of their medical treatment system consisted of
having doctors specialize in one area of the body. For example, there were doctors that
specialized in illnesses of the head, which included the illnesses of the brain. Ancient Egyptians
understood the brain as being the primary site of mental function, emotion, and “being” (Nasser,
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1987), and routinely assessed the mental state of all their patients, whether they came in with a
head ailment or not, due to their belief that the mind was the center of consciousness and
function (Karenberg and Leitz, 2001).
Nasser (1987) elaborates on some of the health care practices employed by the ancient
Egyptians for ailments of the head. For example, it was common for ancient Egyptian doctors to
use the “principle of transfer” in their medical practice to alleviate ailments of the head. This
would involve rubbing the head of a fish on the head of the sick individual in an effort to transfer
the pain from the sick individual to the fish head. To support this, Okasha and Okasha (2000)
explain that Egyptians viewed the brain as the center of the nervous system and believed that
ailments of the brain disturbed the normal function of the body. Egyptian doctors commonly
used a balanced mix of magic and medicine for their patients. Many times, patients would be
seen by a specialty doctor, a priest, a magician, a dream interpreter, and sometimes kingship
(Todd, 1921).
Ancient Egyptian medicine recognized ailments of the brain, which allows us to
hypothesize that they employed measures to treat individuals with neurodegenerative diseases.
Various excerpts from the Ebers Papyrus detail possible accounts of dementia (Table 1).
Additional accounts that are not detailed in Table 1 include an excerpt from the 24th century BC
by the Egyptian Vizier Ptahhotep that says, “Eyes are dim, ears are deaf, strength is waning and
one is weary, the mouth silenced speaks not, the heart void does not recall the past. What age
does to people is bad in every respect” (Karenberg and Leitz, 2001). Also, Stern (1989) lists an
excerpt from the Edwin Smith papyrus that details a king with “divine old age had slackened his
mouth. He casts his spittle upon the ground and spat it out.” Stern (1989) and other scholars
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believe this is in reference to Parkinsonian dribble, however this is simply a speculation since
scholars may likely never be able to verify this.
In accompaniment with physician visits, ancient Egyptians used a wide variety of herbs,
plants, and roots to treat illnesses of the mind, and to sharpen the mind and improve memory.
Table 55 lists the plant species found in ancient Egypt that were used by the populous to treat the
ailments described in this thesis. While we can never be certain that these plants were used to
combat neurodegenerative diseases such as Alzheimer’s or Parkinson’s, we can speculate that
these plants were used in concert with specialized medical treatment from a physician of the
head to treat cases of dementia.
Table 39: List of plants used to treat ailments of the mind in ancient Egypt. Adapted from Ali et
al., 2013; Dua et al., 2009; Mahdy et al., 2012; Aboelsoud, 2010; Perry et al., 1999
Plant Species

Common
Name
Aloe Vera
Frankincense

Part of
Plant Used
Dried Juice
Gum

Turnip

Root

Black Mustard
Indian
Gooseberry
(Amla)
Golden Shower
Tree
Black Cumin
Black Pepper

Seeds
Fruits

Anti-aging
Improves memory, considered to restore
organs to proper function

Fruits

Expectorant for brain problems

Seeds
Seeds

Rheum palmatum
L.
Rosmarinus
officinalis L.
Ruta graveolens L.

Chinese
Rhubarb
Rosemary

Stem

Common Rue

Leaves

Salvia triloba L.

Greek Sage

Aerial parts

Syzgium
aromaticum (L.)

Clove

Pud

Improves memory
Enhances memory, sharpens the mind,
used to treat strokes, used for headaches
Anti-aging, helps to improve memory,
considered to help maintain healthy mind
Helps to sharpen the mind, treats anxiety
and depression, assists with poor memory
Used to treat strokes, assists with memory
enhancement, used to treat epilepsy,
alleviates tremors
Used as a nerve tonic, anti-inflammatory,
considered to enhance memory
Considered to enhance memory,
stimulates the brain, used as an antidepressant

Aloe vera
Boswellia sacra
Flueck
Brassica rapa ssp
rapa
Brassica nigra L.
Emblica officinalis
Gaertn
Cassia fistula L.
Nigella sativa L.
Piper nigrum L.

Aerial parts
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Traditional Uses
Improves mental capacity, anti-depressant
Anti-depressant, improves brain function,
cures forgetfulness
Anti-aging

Step Four: Implications for Group and Individual Agency and Identity
Individuals with dementia in Kellis were most likely taken care of by family members
within the home. Again, while we can never be certain of this, we can infer familial dynamics
from burials at Kellis 2. It is hypothesized that the burial arrangements in the Kellis 2 cemetery
was primarily organized by kinship, meaning that individuals within a family unit were buried
together (Molto, 2002). The cemetery represents a communal burial ground for the artisans of the
Kellis community (Molto, 2001). Burials at the Kellis 2 cemetery contained minimal burial
goods, such as beads, and the bodies were wrapped in linen (Bowen, 2003).
Mortuary analysis shows that while the dead were buried with minimal items, it does not
minimize the sentiment. The individuals of Kellis may have buried their dead with items that
simply reflected the artisan economy and community to which they were a part of. The burials of
the Kellis 2 cemetery reflect a strong sense of family within the community that once lived there,
which allows us to infer that there was a strong sense of family support for sick individuals. This
is reflected by burial patterns in which individuals with specific pathological conditions such as
leprosy were buried among everyone else, and not segregated (Donoghue et al., 2005). If ancient
Egyptians truly followed a specialized medical treatment system, relied on herbal remedies and
medications, and sustained a strong sense of familial identity, we can infer that the care for
individuals with neurodegenerative diseases was ample. Individuals with neurodegenerative
diseases often lose proper cognitive function, which can hinder or eliminate the sense of
individual agency. However, based on the burials at Kellis 2, it is likely that individuals with
neurodegenerative diseases were cared for by family members.
The burden of care most likely fell to the immediate family members within the home
sphere, since the afflicted individual is unlikely able to care for themselves. This includes
difficulty completing daily activities and general self-maintenance activities such as bathing or
122

eating. The life span of someone with a neurodegenerative disease usually lasts anywhere from
4-8 years after diagnosis, which entails a long period of time dedicated to care and support by
family members. Caring for someone for this length of time would definitely affect the family
identity and dynamic until the afflicted family member passed. There can be no question that an
individual with a neurodegenerative disease would not survive without proper care and support.
While we can speculate that care was derived from family members based on the burials at Kellis
2, we can never know if care was also received from the greater community at Kellis. However,
since care for someone with a neurodegenerative disease is a very involved process, they likely
received general community engagement. The process of caring for someone with Alzheimer’s
or Parkinson’s disease is a very labor intensive and involved process, that likely required around
the clock care from a family member in Kellis.

Summary of Discussion
This study revealed eight individuals from the Kellis 2 sample with possible neurological
diseases. These individuals include K2-398, K177-1, K280-1, K281-1, K261-2, K089-2, K306-4,
and K275-2. The individual and specific breakdown of the health of these individuals can be
seen in table 38. Although this chapter delves into specific reasoning as to why these individuals
may have neurological diseases, we can never be certain of these speculations since they lived in
the past. However, we can more definitively define what their health care practices may have
looked like if these individuals were to have a neurological disease.
In the first step of the bioarchaeology of care theory, we needed to diagnose the
individuals with a possibly debilitating disease. The neurological diseases identified within the
Kellis sample are Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, prion disease,
and mood disorder(s), as referenced in table 38. Step two required knowledge of how the
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disease(s) would inhibit their daily life and functions. To do this, we outlined accounts from
doctors and researchers explaining the crippling effect these diseases can have on an individual.
Generally, individuals with these diseases have issues with decision-making, counting,
remembering, learning, understanding, and communicating (Burns et al., 2000). Additionally,
these neurological diseases are characterized by impaired motor functions, autonomic
dysfunctions, neuropsychiatric issues, sleep disorders, and dementia (Prizer and Browner, 2012).
This is a brief synopsis of the earlier discussion outlining the need for daily care for individuals
with these neurological diseases.
For the third step we needed to develop a model of care. Ancient Egyptian medical
system recognized ailments of the brain, which allows us to hypothesize that they employed
measures to treat individuals with neurodegenerative diseases. The third step allowed us to dive
into specialty medical treatments within ancient Egypt, as seen by the establishment of doctors
who specialize in illnesses of the head and mind. Additionally, table 39 outlines the various
plants, herbs, and roots used by physicians in the past to treat ailments of the mind, emphasizing
the idea that ancient Egyptians were equipped to deal with neurological diseases.
Lastly, step four required an exploration into how individual and group agency is affected
by those with neurological diseases. As stated previously, those within ancient Egypt with
neurological diseases were most likely looked after by family members. Burial organization at
Kellis 2 affirms the notion of strong familial ties since family members were buried together.
Assuming this same notion, we can hypothesize that family ties were just as strong during life as
they appear to be in death. This discussion of familial agency as a group of caregivers is
reaffirmed by the research of modern academics who show that the majority of the caregiving
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responsibilities are left to the immediate family members of the afflicted. With this in mind, it’s
not outside the scope of possibilities that this same dynamic also persisted in the past.

125

CHAPTER SIX:
CONCLUSION
The results from the trace element analysis of hair samples collected from the Kellis 2
cemetery indicate that some individuals in this community may have suffered from
neurodegenerative diseases. While we can never truly know if the individuals in this study
suffered from a neurodegenerative disease, their trace element profiles allow us to hypothesize a
likely probability via differential diagnosis that they did in fact suffer from these ailments. Due
to the high prevalence of neurodegenerative diseases today, like Alzheimer’s and Parkinson’s, it
is likely that individuals in the past commonly experienced these diseases as well. Medical
treatments in ancient Egypt equipped physicians to deal with ailments of the head, as seen
through their specialized medical plans, knowledge of medicinal herbs and plants, and the
accounts of dementia listed in various ancient papyri.

Implications
Research concerning neurodegenerative diseases in the archaeological literature is rare to
non-existent. Although there is research into neural tube defects, the realm of literature regarding
neurological health and disease within bioarchaeological context is abysmal. This research could
open the door to various avenues of analysis for neurological health and disease within the
archaeological record at different sites and time periods. While different methods for the study of
neurological health and disease within bioarchaeology should be explored, this study is the first
of its kind to explore neurological health and neurodegenerative disease within bioarchaeology.
Going forward, studies should explore different methodologies, sample groups, and materials to
understand neurological health within the past.
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The study and identification of neurodegenerative diseases in this context allows us to
understand the longevity of these diseases, while also understanding how it affected the daily
lives of individuals and groups in the past. Additionally, this study verifies that the individuals of
Kellis experienced many illnesses due to a maladaptive environment rather than the development
of illness due to poor genetics. The people of Kellis were not sequestered in their environment,
since we have documentation exploring the trade routes they used. So, it appears to be their
environment that is causing health issues and disease rather than poor genetics.

Limitations
The limitations of this study include the small sample size used across the two groups.
However, as is common in most archaeological populations, most individual in Kellis did not
survive to be elderly. According to Dupras et al. (2016) only 7.1% of adults lived to be over the
age of 51 within the Kellis 2 population. The mean age of death for males at Kellis was 34.5
years and 42.6 for females, thus reducing the sample size for this study. Lastly, the possibility of
skewed results from the trace element analysis was a considerable limitation of this study. While
it is most likely that all trace elements entered the body in life, there is always the possibility of
trace elements being incorporated via diagenetic processes and thereby negatively impacting the
results and skewing the data.

Future Directions
Further research into neurological disease via archaeological analysis is necessary to
continue the conversation of health in the past. While archaeologists can never fully
understand the spectrum of health in the past, alternative methods of health investigations, in
addition to macroscopic skeletal analysis, should be considered. This study is a prime
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example of such efforts, combining macroscopic skeletal analysis and trace element analysis.
Dismissing conversations of neurological health in the past overlooks vital elements of
ancient healthcare practices that archaeologists should explore. Additionally, studies of
neurological diseases in the past should include a larger spectrum of elements to analyze,
such as lead or nickle. Combining additional elements with the six used for this study would
give researchers a more holistic understanding of an individuals health status in the past.
Additionally, lead is regarded as an integral element within the pathogenesis of neurological
diseases, and would provide researchers with a more in-depth understanding of neurological
health in archaeological contexts.
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